

# Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/111157/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Meltzer-Brody, Samantha, Howard, Louise M., Bergink, Veerle, Vigod, Simone, Jones, Ian ORCID: <https://orcid.org/0000-0001-5821-5889>, Munk-Olsen, Trine, Honikman, Simone and Milgrom, Jeannette 2018. Postpartum psychiatric disorders. Nature Reviews Disease Primers 4 , 18022. 10.1038/nrdp.2018.22 file

Publishers page: <http://dx.doi.org/10.1038/nrdp.2018.22>  
<<http://dx.doi.org/10.1038/nrdp.2018.22>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



# Postpartum Psychiatric Disorders

**Samantha Meltzer-Brody<sup>1</sup>, Louise M Howard<sup>2</sup>, Veerle Bergink<sup>3</sup>, Simone Vigod<sup>4</sup>, Ian Jones<sup>5</sup>,  
Trine Munk-Olsen<sup>6</sup>, Simone Honikman<sup>7</sup>, Jeannette Milgrom<sup>8</sup>**

<sup>1</sup> The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

<sup>2</sup> Kings College, London, United Kingdom

<sup>3</sup> Department of Psychiatry and Department of Obstetrics, Gynecology and Reproductive Medicine,  
Icahn School of Medicine at Mount Sinai, New York

<sup>4</sup> University of Toronto, Toronto, Canada

<sup>5</sup> National Centre for Mental Health, MRC Centre for Neuropsychiatric Genetics and Genomics,  
Division of Psychological Medicine, Cardiff University, Wales, United Kingdom

<sup>6</sup> Aarhus University, Aarhus, Denmark

<sup>7</sup> University of Cape Town, Cape Town, South Africa

<sup>8</sup> Parent-Infant Research Institute and University of Melbourne, Victoria, Australia

## Acknowledgements

We would like to thank Dr. Alan Gemmill from Parent-Infant Research Institute and Holly Krohn from the University of North Carolina at Chapel Hill for their contributions to the preparation of this manuscript.

## Competing interests

S.M-B. has received research grant support to The University of North Carolina at Chapel Hill from Sage Therapeutics and Janssen. L.M.H. is funded through a National Institute for Health Research (NIHR) Professorship in maternal mental health (NIHR-RP-R3-12-011). V.B. is supported by NWO (VENI 91616036 and Clinical Fellowship 90715620 ) and the EMC fellowship. IJ is a trustee of Action on Postpartum Psychosis and the Maternal Mental Health Alliance and is supported through the National Centre for Mental Health grant from Health and Care Research Wales. All other authors declare no competing interests.

## Author contributions

Introduction (S.M-B. and all co-authors); Epidemiology (T.M-O.); Mechanisms/pathophysiology (I.J. and S.M-B.); Diagnosis, screening and prevention (L.M.H., S.H. and J.M.); Management (S.V. and V.B.); Quality of life (J.M.); Outlook (All); Overview of Primer (S.M-B.).


## 38   **Abstract**

39   Pregnancy is a complex and vulnerable period that presents a number of challenges to women,  
40   including the development of postpartum psychiatric disorders (PPDs). These disorders can include  
41   postpartum depression and anxiety, which are relatively common, and the rare but more severe  
42   postpartum psychosis. In addition, other PPDs can include obsessive–compulsive disorder, post-  
43   traumatic stress disorder and eating disorders. The aetiology of PPDs is a complex interaction of  
44   psychological, social and biological factors, in addition to genetic and environmental factors. The  
45   goals of treating postpartum mental illness are reducing maternal symptoms and supporting  
46   maternal-child and family functioning. Women and their families should receive psychoeducation  
47   about the illness, including evidence-based discussions on risks and benefits of each treatment  
48   option. Developing effective strategies in global settings that allow the delivery of targeted therapies  
49   to women with different clinical phenotypes and severities of PPD is essential.

50  
51

## [H1] Introduction

Pregnancy and the first year after childbirth (which collectively can be referred to as the perinatal period) is arguably one of the most transformative times in a woman's life. This timeframe is also a complex and vulnerable period that presents a number of challenges for women. In particular, an increased risk for onset or worsening of psychiatric illness including mood disorders, anxiety disorders and psychosis exists during the first three months postpartum. All types of psychiatric disorders can occur during the postpartum period, with many chronic disorders starting before pregnancy and persisting throughout pregnancy into the postpartum period<sup>1</sup>. In this Primer, we focus specifically on the postpartum psychiatric disorders (PPDs). Collectively, the postpartum psychiatric disorders (PPDs) can include postpartum depression, which is relatively common; common anxiety disorders such as generalized anxiety disorder (GAD; which can include anxieties about the health of the baby); post-traumatic stress disorder (PTSD; which can occur due to a traumatic childbirth experience or can reflect pre-existing symptoms due to previous traumas before conception or during pregnancy); and the rarer, but usually severe presentation of postpartum psychosis. Other PPDs include eating disorders (which can worsen or recur postpartum, particularly when the infant is undergoing weaning), and obsessive-compulsive disorder (OCD)



In pregnancy, depressive and anxiety disorders are common with recent population estimates of 11% for depressive disorders and 15% for anxiety disorders.<sup>2</sup> Further, antenatal anxiety and depression are one of the greatest risk factors for postpartum psychiatric disorders (PPD).<sup>3</sup> Inadequate social support and a history of adverse life events increases the risk for PPDs in all countries and levels of society<sup>4, 5</sup>. However, this risk is increased in poorer socioeconomic populations and lower income countries, due to poverty and limited access to health care.<sup>6</sup>

In recent years, awareness of the potentially serious adverse consequences in both the mother and the baby associated with untreated perinatal psychiatric illness has increased. Maternal suicide due to postpartum mood disorders (including unipolar and bipolar depressive disorders) is a leading cause of maternal mortality.<sup>7, 8, 9</sup> In addition, perinatal mood disorders are associated with an increased risk for low birth weight and premature birth, impaired mother-infant attachment, and infant malnutrition during the first year of life<sup>10, 11</sup>.

In this Primer, we focus on maternal PPDs, as they are common, morbid, and have a growing literature on the underlying pathophysiology. These disorders should not be confused with the so-called 'baby blues', which are usually described as transient mild mood and anxiety symptoms that often persist  $\leq 2$  weeks and usually resolve spontaneously with no sequelae.<sup>12</sup> If the symptoms of the 'baby blues' worsen and/or persist, they are considered PPDs. Herein we discuss the epidemiology of PPDs, and their underlying mechanisms and pathophysiology. We mainly focus on maternal PPDs, although paternal disorders are mentioned in some instances (Box 1). Importantly, we review the latest evidence on diagnosis, screening and prevention as well as management of PPDs. Lastly, we hope to put in context the public health impact of these disorders on mothers, their children and families to encourage wide scale adoption of strategies that make maternal mental health a global priority<sup>13</sup>.

## **[H1] Epidemiology**

Data on the incidence of postpartum depression are from studies conducted in countries across the world, and variable incidence and prevalence are reported between countries<sup>14</sup>. By comparison, studies estimating the incidence and prevalence of postpartum psychosis are primarily carried out in Europe<sup>15</sup>, and demonstrate less variability in reported incidence and prevalence<sup>16, 17</sup>. Several methodological factors have influenced these differences.<sup>18</sup> For example, particularly for postpartum depression, the definition of the postpartum period is variable between studies, and has been defined as up to 4 weeks, 3 months, 6 months or 12 months postpartum<sup>19</sup>. Differences in study designs, such as using different tools to define case-groups and phenotypes can lead to variability in the reported number of cases. Data sources for postpartum depression and postpartum psychosis include self-reports and interviews, in addition to some population-based register data<sup>16</sup>. Moreover, the incomplete availability of longitudinal data that is needed to distinguish between first-time and recurrent psychiatric episodes might impede calculations of the true incidence and prevalence of PPDs. Consequently, a variation in reported incidence and prevalence could be explained by differences in methodologies between studies, which make direct comparisons difficult. In addition, the diverse symptoms of PPDs pose specific challenges to the estimation of prevalence and incidence of these disorders<sup>20</sup>.

As the literature surrounding the epidemiology of PPDs continues to grow with well-designed studies, we will have a better understanding of if differences in the incidence and prevalence of postpartum depression and postpartum psychosis are due to local/regional and national differences, or if the differences are due to variable study designs and data sources. This knowledge will assist hypothesis generating that might provide clues for the aetiology of these disorders.

## **[H2] Mood disorders and anxiety**

Postpartum depression, comprising major depressive disorder and subthreshold depression, has an estimated point prevalence of 13% in high-income countries<sup>11</sup>, and ~20% in low-income and middle-income countries, 3 months postpartum (Box 2)<sup>21</sup>. In women with a history of any eating disorder, the prevalence of postpartum depression has been estimated at 35%<sup>22</sup>. Studies of postpartum depression often rely on self-reported questionnaires, including the commonly used Edinburgh Postnatal Depression Scale (EPDS)<sup>14, 23</sup>.

Although the prevalence estimates for postpartum mood disorders ranges between studies, guidelines are available that state that these disorders pose substantial public health risks and consequently, must be identified and treated<sup>24,25</sup>. Moreover, there is consensus that childbirth is a strong and potent risk factor for bipolar disorder. Indeed, the risk of underlying bipolarity in first-onset depression that occurs in the postpartum period is higher than in first-onset depression that occurs outside the perinatal period. In addition, women with bipolar disorder have a high risk of postpartum episodes, including depression, anxiety, mania and psychosis<sup>26, 27</sup>.

The estimated prevalence of postpartum anxiety disorders is ~10%, with a prevalence of 6% for GAD<sup>28</sup>. Anxiety disorders have substantial comorbidity with postpartum depression and other disorders, including postpartum PTSD, eating disorders and the exacerbation of personality disorders<sup>17</sup>.

## **[H2] Postpartum psychosis**

The onset of a severe mental disorder requiring acute inpatient psychiatric treatment in the first postpartum months is ~1 per 1,000 births<sup>29-32</sup>, and are considered some of the most severe forms of illness in psychiatry<sup>18</sup>. These severe psychiatric disorders that have an onset in the immediate postpartum period are often called postpartum psychosis, which is an umbrella term for disorders recorded as, for example, mania, mixed episodes, psychotic depression, or psychosis not otherwise specified<sup>33</sup>

[. Women with bipolar disorder have the highest risk for postpartum psychosis than women with other psychiatric diagnosis, as the risk for postpartum relapse in women with bipolar disorder is on average 37%<sup>18</sup>. However, variations also occur within bipolar disorder, as the risk of a severe episode \(ie postpartum psychosis\) is greater for women with bipolar I disorder than women with bipolar II disorder<sup>34</sup>. Additionally, the risk of symptom recurrence is particularly high for women with bipolar disorder who are not receiving medication during pregnancy<sup>18</sup> .](http://journals.sagepub.com/doi/abs/10.1177/0004867414564698?url_ver=Z39.88-2003&rft_id=ori%3Arid%3Acrossref.org&rft_dat=cr_pub%3Dpubmed&)

Relapse of psychosis can also occur in women with other psychiatric disorders, such as women with schizophrenia, although this is less common<sup>35</sup> (~16% within the first 12 months postpartum) Yes—it has been added now.  [, and manifests differently from what is observed in women with bipolar disorder<sup>16</sup>.](https://www.ncbi.nlm.nih.gov/pubmed/19188541)

Despite the widespread use of the term postpartum psychosis, this diagnosis is not recognized in current classification systems, including both ICD-10 and DSM-5 <sup>36</sup>. However, it is clear that psychotic episodes are more prevalent during the postpartum period than in other periods in a woman's life, and evidence clearly suggests a particular vulnerability in women with bipolar disorder <sup>29</sup>.

In women with severe postpartum psychiatric illness, maternal suicide is often a predominate concern. Although maternal suicide is a leading cause of maternal mortality<sup>7</sup>, the rates of completed suicide in postpartum women are lower than those in age-matched women without children<sup>37</sup>. Nonetheless, the prevention of maternal suicide is paramount and requires careful monitoring during the postpartum period and possibly extending beyond the first year. For example, one study demonstrated that most postpartum suicides occurred between 9 and 12



months postpartum and that the perinatal suicides were by highly lethal means (such as via firearm), suggesting that limiting follow-up to 1, 3 or 6 months postpartum might be insufficient.<sup>38</sup>

## **[H1] Mechanisms/pathophysiology**

As previously mentioned, childbirth is one of the most potent triggers of psychiatric illness. Given that postpartum mental health disorders are one of the few occurrences in psychiatry whereby a biological trigger occurs at a known time point, elucidating the pathophysiology of these disorders may shed light on the mechanisms of mood and psychiatric disorders more broadly, and is vital for developing new treatment approaches.

The aetiology of all psychiatric disorders, including PPDs, is a complex interaction of psychological, social and biological factors, including the effect of genetic and environmental influences on risk (Figure 1)<sup>12</sup>. The involvement of particular combinations of aetiological factors differs between specific PPDs<sup>34</sup>; for example, biological factors might have a greater role in the triggering of postpartum psychosis, whereas psychosocial factors might have an important contribution in postpartum depression.<sup>34</sup> These are areas of intense investigation and future research is needed to extend our understanding of the many ways that psychological and biological processes interface. Stopping or changing medications in women with a prior history of psychiatric disorders due to concerns about the safety of medication during pregnancy could be considered a simple explanation for the triggering of PPDs. However, continuing medication in pregnancy is protective against mood disorders in a subset of patients<sup>39</sup>. Similarly, discontinuation of medication does not guarantee that a woman will relapse<sup>40</sup>. However, there is much that is still not understood about PPDs and the onset of PPDs reflects the outcome of many different pathways that manifest in vulnerable women. Future research will need to disentangle the mechanisms of depression in women before, during and after pregnancy to increase our understanding of the similarities and differences between perinatal depression and depression occurring at other times in life. We will

next discuss current theories on psychosocial and biological contributions that increase risk for PPDs.

## ***[H2] Psychosocial factors and comorbidities***

Psychological and social stressors contribute to the development of maternal PPDs and are associated with poorer outcomes in the infants or children<sup>41, 42</sup>. In particular, adverse life events and a history of trauma have a greater prevalence in women that develop postpartum mood disorders, compared with mood disorders outside of the perinatal period<sup>4, 43, 44</sup>. A history of adverse early life experiences can substantially affect a mother's ability to have a strong attachment with her infant<sup>45</sup>, and adverse parent–infant interactions and worse attachment are associated with development of PPDs<sup>46-48</sup>.

Social support has a vital role in either contributing to or mitigating the impact of postpartum mood disorders on both the mother and child<sup>49</sup>. Indeed, social support, or the degree of tangible support provided from the social network of the mother and from the partner (such as financial support or assisting with infant care), have the greatest effects on postpartum depression<sup>50</sup>.

Other psychosocial risk factors include a past history of a mood disorder, which is consistently associated with an increased risk of postpartum depression and postpartum psychosis<sup>34</sup>. In addition, although the strength of the association between risk factors and PPDs is variable between high-income countries and low-income and middle-income countries, one of the strongest psychosocial risk factors in both settings is domestic violence and previous abuse, including abuse during childhood.<sup>4, 51</sup> Other risk factors with a medium to strong association with PPDs include marital difficulties, migration status and antenatal depression or anxiety<sup>17, 52</sup>. In addition, poverty, young age (between 14 and 21 years of age), substance misuse, increased parity, multiple births, an unwanted pregnancy, neuroticism, pregnancy complications including obesity and comorbidities

(for example diabetes, hypertension and pre-eclampsia) and neonatal problems are associated with PPDs<sup>17</sup>.

## **[H2] Genetic factors**

Data from twin and adoption studies have implicated genetic factors in the aetiology of psychiatric disorders outside of the perinatal period, including schizophrenia and mood disorders<sup>53, 54</sup>.

However, only recently have genetic investigations, primarily of postpartum depression and postpartum psychosis, been conducted.

Genetic epidemiological and linkage studies for postpartum depression have demonstrated the involvement of genetic factors<sup>55, 56, 57</sup> and two studies have demonstrated the increased heritability of postpartum depression compared with depression outside of the perinatal period<sup>58, 59</sup>. To date, studies have suggested that episodes of postpartum psychosis are a marker for a more-familial form of bipolar disorder and that the puerperal triggering of bipolar illness is familial.<sup>60, 61</sup> However, a genome-wide association study (GWAS) for either postpartum depression or postpartum psychosis using modern genomics methods has not yet been carried out. Future genetic studies of postpartum mood disorders using modern genomics methods will require international collaborations and consortia to include large number of patients; these studies are currently underway<sup>62, 63</sup>.

Psychological stressors and early life adverse events have a lasting negative impact and can result in pathophysiological changes and altered gene expression due to increased allostatic load (the cumulative stress on the body that is a sum of lifetime exposure to stress)<sup>64</sup>. Potential mechanisms underlying how stressful life events change gene expression include epigenetic modification (such as DNA methylation and histone modification that change DNA accessibility and chromatin structure, subsequently regulating gene expression)<sup>65</sup>, changes in transcriptional control of stress-responsive pathways<sup>66</sup>, and shortened telomere length<sup>67, 68</sup>. Epigenetic alterations have been

reported in two genes, *HP1BP3* and *TTC9B*, which have different methylation patterns in women with postpartum depression, depending on whether the mood symptoms begin during pregnancy and continue into the postpartum period, compared with symptoms that develop postpartum only<sup>69, 70</sup>. These data indicate that different gene patterns might arise based on the timing of symptom onset. However, given the history of non-replication in many genetic studies, these findings require replication and overall, the mechanism of action in postpartum depression remains to be established.

## **[H2] Sleep Disruption**

An almost universal feature of pregnancy and childbirth is disruption to sleep. In addition, sleep and circadian rhythm disruption can trigger the onset of psychiatric disorders, particularly episodes of mania in the postpartum period<sup>71, 72</sup>. Thus, that circadian rhythm disruption has not received more attention as a potential mechanism in PPDs is surprising.

Numerous studies have demonstrated profound changes in maternal sleep patterns during the perinatal period. Pregnant women experience poorer subjective sleep quality, increased waking, and more sleep-wake transitions than women who are not pregnant<sup>73</sup>. In the postpartum period, new mothers have frequent night waking, decreased night-time sleep, increased daytime napping, and a more irregular sleep-wake schedule, which is speculated to increase the risk of PPDs<sup>74</sup>. The mechanisms underlying the reported disrupted maternal sleep patterns in the perinatal period have been reported in two cross-sectional studies. The first study demonstrated a blunted melatonin amplitude in postpartum women, compared with non-pregnant women,<sup>75</sup> and the second study demonstrated differences in circadian rhythms between perinatal women with depression and perinatal women without depression; indeed, in the second study, women with depression had clinically-significant circadian rhythm phase shifts.<sup>74</sup> Further research is needed to better

understand the mechanisms of sleep disruption that might trigger PPDs and potential interventions that target the circadian rhythm disruptions during the perinatal period<sup>76</sup>.

## ***[H2] Reproductive Hormones***

One important hypothesis for the aetiology of PPDs is based on the temporal onset of these disorders immediately after childbirth, which is a time of major physiological change for women, including alterations in hormonal systems. Multiple lines of evidence have demonstrated that fluctuations in reproductive hormones (such as oestrogen and progesterone) during the perinatal period are substantial contributors to the development of postpartum mood disorders in vulnerable women. Gonadal steroid hormones (such as oestrogen and progesterone) are produced at very high levels during pregnancy, but rapidly decrease to pre-pregnancy levels after childbirth. One study simulated this pattern of hormone expression and demonstrated substantial mood symptoms (such as sadness, anhedonia and anxiety) during the withdrawal period in five of eight women with a history of postpartum depression, but in none of the eight women with no history of postpartum depression<sup>77</sup>. Thus, women who are vulnerable to postpartum psychiatric episodes might not have gross abnormalities in endocrine physiology (such as no differences in the absolute levels of hormones), but might have an abnormal response to the hormonal fluctuations of pregnancy and childbirth.

Reproductive hormones have important functions in the central nervous system. Oestrogen and progesterone receptors are expressed throughout the brain and can modulate neurotransmission and neuroplasticity via both genomic and non-genomic mechanisms. For example, rodent studies have shown that ovariectomy reduces and estradiol administration increases brain-derived neurotrophic factor (BDNF) levels in the hippocampus and the forebrain<sup>78</sup>; BDNF levels are decreased by stress and depressive symptoms and are increased following treatment with antidepressants<sup>79</sup>. The rapid fall in oestrogen levels in the postpartum period might, therefore,

reduce BDNF levels and increase susceptibility to PPDs in women who are vulnerable. Similarly, progesterone has an important role in regulating neurotransmitter synthesis, release and transport<sup>80</sup> and, has been shown to up-regulate BDNF expression in the hippocampus and cerebral cortex in rodent models<sup>81</sup>.

The neurosteroid, allopregnanolone, which is a major metabolite of progesterone, might also have an important role in the aetiology and, potentially, in the treatment of postpartum depression<sup>82, 83</sup>. Allopregnanolone is a positive allosteric modulator of synaptic and extrasynaptic GABA<sub>A</sub> receptors<sup>84</sup>,<sup>85</sup> and animal models have demonstrated that intravenous allopregnanolone administration significantly reduces anxiety and depressive symptoms<sup>86</sup>. Allopregnanolone concentrations reach peak physiological levels during the third trimester of pregnancy and rapidly decrease following childbirth<sup>87, 88</sup>. The failure of GABA<sub>A</sub> receptors to adapt to the rapid fluctuations in allopregnanolone levels at childbirth is hypothesized to be a trigger for postpartum depression<sup>89, 90</sup>. This line of inquiry is being further explored by the development of brexanolone (a proprietary formulation of allopregnanolone) as a treatment for postpartum depression<sup>91,92</sup>.

Oxytocin is a neuroactive hormone that supports childbirth, lactation, maternal behavior, and social bonding<sup>93</sup>. Some studies have demonstrated an inverse association between circulating oxytocin levels and postpartum depression<sup>94</sup> although other studies have not found this<sup>95</sup>. The alterations in the oxytocin system that occur during pregnancy and childbirth do not occur in isolation, and the role of oxytocin in postpartum depression is likely to be complex and not accounted for by absolute levels, similar to the roles of other neuroactive hormones<sup>83</sup>.

Further, recent neuroimaging data increases our understanding of the neurobiological basis underlying perinatal mood disorders and the development of maternal behavior. Indeed, one study demonstrated that the effects of a polymorphism in *BDNF* (*BDNF* Val<sup>66</sup>Met) on hippocampal function are selectively modulated by estradiol<sup>96</sup>. This work lends further data to the importance of the role of sex steroids on the regulation of behavioural functions associated with psychiatric

disorders, such as emotional processing, arousal, cognition, and motivation. Thus, it follows the involvement of sex steroids of brain function could be revealed using neuroimaging. Indeed, multiple cortical and subcortical brain regions have altered activity observed using functional MRI or PET (such as, measurement of brain MAO-A<sup>97</sup>) in mothers with depression, in response to infant and non-infant emotional cues<sup>98, 99</sup>. These alterations might impact important neuronal networks that are associated with learned reward, reaction to stimuli, stress, motivation and executive functioning. In addition, recent research from functional MRI studies shows distinct neurobiological patterns that distinguish anxiety and depression occurring in the perinatal period, compared with other times of a woman's life, and these patterns may have significant impact on the mother-infant relationship<sup>100</sup>.

## **[H2] Other factors**

**[H3] Stress axis.** The postpartum period is a time of great flux for the HPA stress axis<sup>101</sup>. Indeed, alterations in the hypothalamic–pituitary–adrenal (HPA) axis occur during pregnancy, such as corticotropin-releasing hormone (CRH) production by the placenta, resulting in significantly increased levels during pregnancy, which abruptly decline postpartum<sup>102</sup>, and rising levels of gonadal steroids that contribute to puerperal hypertrophy of the pituitary and adrenal glands, leading to increases in ACTH and cortisol levels<sup>103</sup>. CRH fluctuations during the perinatal period might trigger HPA axis dysregulation and contribute to the onset of depressive and anxiety symptoms in a subset of vulnerable women <sup>104</sup>; however, inconsistent findings have been reported<sup>105, 106</sup>.

**[H3] Thyroid hormones.** Thyroid hormones have been implicated in the development of postpartum mood disorders. Thyroid binding globulin (TBG, which transports thyroid hormones in the blood) concentrations increase during pregnancy and might be an index of sensitivity to

elevated oestrogen levels. Some data also suggest that decreased [Au:OK? YES] TBG levels are a predictor of perinatal depression<sup>107</sup>. In addition, first-onset postpartum autoimmune thyroid disorders often co-occur with postpartum mood disorders<sup>108</sup>. The occurrence of both disorders coincides with the postpartum rebound phenomena of the maternal immune system, suggesting an overlap in aetiology<sup>109</sup>. Supporting this hypothesis, women with increased thyroid peroxidase antibodies during pregnancy have an increased risk for postpartum psychiatric episodes<sup>109, 110</sup>. Accordingly, the assessment of thyroid function (such as measurement of thyroid-stimulating hormone levels, tri-iodothyronine (T3) and tetraiodothyronine (T4)) is an essential part of diagnostic evaluations in women with postpartum psychiatric episodes.

**[H3] Neuroimmune pathways.** Neuroimmune pathways might also have a role in the pathophysiology of postpartum mood disorders<sup>101, 111-113</sup>. The transition from pregnancy into the postpartum period is characterized by an accelerated immune response (mediated through both pro-inflammatory and anti-inflammatory mediators for healing and involution) during labor that continues into the early postpartum period<sup>114</sup>. Consequently, immune changes at the end of pregnancy might predict postpartum depression. IL-6 levels are increased in women with postpartum depression compared with postpartum women who do not have depression in some, but not all studies.<sup>112,115</sup> However, leptin (a protein hormone made by adipose cells that regulates energy and has inflammatory functions) might also be associated with postpartum depression. Indeed, decreased maternal serum leptin levels during delivery are associated with a higher risk for postpartum depression, and might potentially serve as a biomarker for postpartum depression<sup>115</sup>. Lower levels of Clara cell protein (CC16, an endogenous anti-inflammatory compound) are associated with PPD a few weeks later<sup>116, 117</sup>. Furthermore, decreased levels of  $\omega$ 3 polyunsaturated fatty acids (PUFAs) at the end of the third trimester are suggested to associate with increased risk of PPD in the early postpartum period<sup>118</sup>. The underlying mechanism is hypothesized to be increased peripheral inflammation<sup>118</sup> owing to the anti-inflammatory effects of



ω3 PUFAs. In summary, dysregulation of the crosstalk between the immune system and the HPA-stress axis is hypothesized to be associated with the onset of postpartum depression<sup>101, 119</sup>

Interestingly, first pregnancies are more often followed by psychiatric episodes than subsequent pregnancies, which may illustrate the dysregulation of psychoneuroimmune systems. This effect is hypothesized to be due to the biological differences between first and subsequent pregnancies, and has raised the possibility of an aetiological link with other medical conditions that have a similar increase in prevalence in first pregnancies such as pre-eclampsia<sup>120</sup>. Intriguingly, pre-eclampsia and postpartum psychosis are both associated with immune dysregulation, for example the increased rates of postpartum autoimmune thyroiditis<sup>108, 109</sup> and alterations in immune biomarkers (such as, CNS autoantibodies) in women with postpartum psychosis<sup>121</sup>. In addition, abnormalities in monocyte and T cell function and tryptophan breakdown has been demonstrated in patients with postpartum psychosis or mania, compared with postpartum women without any psychiatric symptoms.<sup>122</sup> Patients with postpartum psychosis had monocytosis and failed to demonstrate the physiological T- cell increase that is normally observed during the postpartum period. These findings support the notion that immune system dysregulation contributes to affective instability and severe postpartum episodes<sup>122</sup>.

Future studies are needed to extend our understanding of the ways in which psychological and biological processes interact in PPDs. For example, social support might exert a stress-buffering effect via the downregulation of stress responses, including inflammatory reactivity to stressors and dampened sympathetic and hypothalamic-pituitary-adrenal (HPA) axis activity<sup>123, 124</sup>.

## **[H1] Diagnosis, Screening and Prevention**

As with all psychiatric disorders, the diagnosis of postpartum depression is reached by a comprehensive clinical interview and diagnostic criteria that provide an operationalised definition of the disorder, using classification systems such as the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)<sup>125</sup> or International Classification of Diseases, Tenth Edition

(ICD10)<sup>126</sup>. Diagnostic criteria are similar across the DSM-5 and ICD-10, which are the two most common classification systems; however, the DSM-5 uses the term 'depression with peripartum onset' to refer to the onset of depression during pregnancy and into the first month postpartum, whereas ICD10 does not use a primary code referring to the perinatal period, although a second code denoting postpartum onset is available (which is not used in practice) . However, the diagnosis of psychiatric disorders is more than a list of symptoms and the impact on symptoms of functioning; diagnosis should also include an understanding of predisposing aetiological factors, triggers and maintenance factors, which are elicited by a comprehensive biopsychosocial assessment<sup>24</sup>.

Postpartum depression is one of the most common postpartum psychiatric disorders, and can be mild and relatively self-limiting lasting only a few weeks, or can be more severe, with severe episodes potentially including psychotic symptoms<sup>17</sup>. Some symptoms of depression such as fatigue, sleep disturbance and appetite disturbance need careful enquiry, as a woman with a baby will be more tired than usual and have disrupted sleep (due to the baby needing a feed), although appetite might not be affected as breastfeeding will stimulate appetite despite a low mood. Checking whether the mother is able to sleep when the baby is asleep, whether the fatigue persists after rest and the interest in food will help establish whether the symptoms are pathological and if they are indicative of postpartum depression. Notably, anxiety might be a prominent symptom in postpartum depression<sup>63</sup>, or can be a symptom of a comorbid anxiety disorder<sup>127</sup>. Diagnostic assessment should evaluate a history of manic or hypomanic symptoms, as first-onset postpartum depression can indicate underlying bipolar disorder<sup>26</sup>. Diagnostic challenges include barriers to disclosing symptoms due to stigma<sup>128</sup> and variations in the manifestation of symptoms, which might reflect cultural or educational differences<sup>129</sup>. In addition, it is important to ensure symptoms are not due to an underlying medical condition such as thyroid disease or an early presentation of first episode psychosis.

Although postpartum psychosis is not included as a primary diagnosis in the DSM-5 or ICD-10, this disorder is still recognised clinically and is usually considered to be a severe mood disorder.<sup>16</sup> Women with postpartum psychosis often have a history of bipolar disorder.<sup>16</sup> Most women have prodromal symptoms before the overt onset of postpartum psychosis; however, some women have acute onset of severe symptoms<sup>130, 131</sup>. Evaluation of women with postpartum psychosis includes assessment of manic, depressed, anxious and psychotic symptoms, and the assessment of the risk of causing harm to herself or her baby. Women with postpartum psychosis can present with either low or high mood (both elation and irritability), or frequently can present with a mixed state, including symptoms of both mania and ; a minority of women have an atypical symptom profile with disorientation and/or disturbance of consciousness<sup>132</sup>. Symptoms can also manifest as delusions, hallucinations, and particularly confusion and perplexity and patients can also have severe mood swings, insomnia, agitation and rapid deterioration. Postpartum psychosis is usually a rapid onset severe psychosis, typically starting within the first 2-4 weeks after birth, and is considered a psychiatric emergency as a lack of self-care and an inability to care for the infant can lead to suicide and/or, in rare cases, infanticide<sup>16</sup>. Accordingly, assessment should be carried out quickly (for example, The National Institute for Health and Care Excellence (NICE) recommend assessment within 4 hours of clinical presentation; in clinical practice this means within 24 hours of the acute onset of severe psychiatric symptoms) to ensure the woman can be cared for safely and appropriately. Excluding other medical disorders, such as cerebral space occupying lesions, thyroid disorders or infections is important as part of the diagnostic work-up. In many cases the mother's partner or family ask for psychiatric evaluation when the mother is irritated or agitated and not aware that she is seriously ill.

Anxiety disorders (such as GAD and panic disorder), OCD and PTSD can all manifest in the postpartum period. OCD is characterised obsessive thoughts. Obsessions are intrusive, repetitive thoughts, images or impulses that are unacceptable and/or unwanted and give rise to subjective

resistance. By contrast, delusions that occur in psychotic disorders are fixed, false beliefs<sup>133</sup> that need appropriate psychological intervention<sup>17</sup>. Postpartum OCD poses a particular diagnostic challenge, as intrusive thoughts about harm befalling the infant (such as, what if I drop my infant or I accidentally cut the infant with a knife when I'm cooking) might be perceived as delusional and could lead to concerns about the safety of the infant. However, these thoughts are not associated with actual direct harm and the obsessions remain very ego-dystonic and highly distressing to the patient. Traumatic childbirth experiences can trigger PTSD, particularly in women with prior histories of trauma<sup>134</sup>. Differentiating the exacerbation of PTSD symptoms in women with past trauma and new onset PTSD owing to traumatic childbirth is important<sup>135</sup>. Past trauma history should include assessment of prior childhood abuse, adult interpersonal or other violence, among other forms of trauma. In addition, many women with PTSD or OCD present with symptoms of anxiety and mood symptoms, making the diagnosis of any one particular disorder a challenge<sup>63, 136</sup>.

Women with a previous history of psychiatric disorders will often experience a worsening of symptoms during the postpartum period, although few studies have examined strategies to mitigate this exacerbation of symptoms<sup>39</sup>. For women without a prior history of psychiatric disorders, the acute onset of psychiatric symptoms in the postpartum period is often highly distressing. However, whether the first onset of psychiatric symptoms in the postpartum period indicates the beginning of a more persistent and chronic mood disorder, or is a condition that will be restricted only to the postpartum period is unclear. This is an important area for future study.

## **[H2] Screening**

Screening for postpartum depression has attracted widespread interest from researchers, clinicians and policy makers due to the high prevalence and associated sequelae in terms of maternal morbidity and adverse child outcomes. In many countries, screening for postpartum depression

495 during routine obstetrical care, including care by health visitors, is inconsistent, and this strategy  
496 has become an area of focus in many countries. In addition, up to 60% of perinatal women with  
497 depression do not seek help <sup>137</sup>. However, given the availability of screening instruments and  
498 effective treatments <sup>138</sup>, Clinical Practice Guidelines and recommendations are increasingly  
499 supportive of routine screening<sup>139, 140</sup>. More generally, international guidelines reflect a consensus  
500 that improved identification of PPDs is vitally important <sup>141,142</sup>. Accordingly, several national  
501 campaign to increase awareness of PPDs are underway, such as the Maternal Mental Health  
502 Alliance<sup>143</sup> in the UK. This alliance is a coalition of organizations that are dedicated to achieving  
503 consistent, accessible and quality mental health care in the first year after giving birth. In addition,  
504 state mandates for perinatal depression screening are increasing in the United States, including  
505 the US Preventive Services Task Force recommendation<sup>140</sup>. However, although this task force has  
506 concluded that the evidence base that is sufficient to recommend screening for perinatal  
507 depression when combined with adequate support systems<sup>25, 140</sup> this conclusion has also been  
508 criticised by others<sup>144</sup>.

509 The most widely researched and used screening tool for postpartum depression is the brief 10-item  
510 Edinburgh Postnatal Depression Scale (EPDS<sup>145</sup>), which was designed to exclude symptoms that  
511 can be normal features of the perinatal period, such as poor sleep, but that are often included in  
512 other self-report measures. A cut-off score of 13 is most commonly used to recommend further  
513 diagnostic assessment<sup>146, 147</sup>. In addition, the EPDS includes question about thoughts of self-harm,  
514 which can help to mobilise risk assessment and can predict suicidal intent<sup>148</sup>. The EPDS has been  
515 used prenatally and validated in a number of languages, its properties are relatively well-  
516 understood <sup>147</sup> and it appears to be highly acceptable in the target population <sup>149,150</sup>. High EPDS  
517 scores can reflect several psychiatric diagnoses. For example, among the 826 screen-positive  
518 women out of a sample of 10,000 women, the most common primary diagnosis was unipolar  
519 depressive disorder (found in 68.5% of women), but almost two-thirds of women had co-morbid  
520 anxiety disorder and 22.6% had a bipolar disorder <sup>151</sup>. These data highlight another potential

benefit of the EPDS: that most women with a false-negative result for unipolar depression have another diagnosable, and potentially treatable, psychiatric condition.

Other generic or perinatal-specific depression measures have been used to identify perinatal depression, but are not as well validated in perinatal women as the EPDS. Other measures include the Postpartum Depression Screening Scale<sup>152</sup>, the Beck Depression Inventory-II<sup>153</sup> and the Patient Health Questionnaire-9<sup>154,155</sup>. Alternatively, two case finding questions (the so-called Whooley questions <sup>141, 156, 157</sup>) can be asked to women to determine whether further mental health assessment should be carried out, and the use of these questions is recommended by NICE guidelines in the United Kingdom. The Whooley questions can also be used to detect any psychiatric disorder, and are not limited to depression<sup>2</sup>.

As previously mentioned, postpartum depression are frequently co-morbid with anxiety (in 4.3% of women). As anxiety substantially impacts maternal functioning and fetal and infant development<sup>28, 158 159</sup>, this has spurred efforts to screen for postpartum anxiety. Three sub-items of the EPDS (the so-called EPDS-3A) can be used to identify perinatal anxiety disorders and sub-syndromal anxiety<sup>160</sup>. Other screening instruments for anxiety disorders include the Perinatal Anxiety Screening Scale (PASS)<sup>161</sup> and the generalized anxiety disorder scale (GAD-7)<sup>162</sup>. Screening tools for perinatal OCD and PTSD are also available, such as the specific perinatal OCD screening scale (The POCS),<sup>163</sup> and a short screening scale for PTSD (SPAN), respectively.<sup>164</sup>.

The utility of routine screening for postpartum psychosis, hypomanic and manic symptoms and bipolar disorder faces several barriers including a lack of evidence base of effectiveness and the reduced predictive value of screening for a relatively rare condition. Despite steady progress in this area<sup>165, 166</sup> a consensus test with well-known precision and an agreed cut-off has not been identified<sup>167,168</sup>. However, the Mood Disorder Questionnaire (MDQ) has shown solid psychometric properties for assessing bipolar disorder and is increasingly used <sup>169</sup>. Taking a full personal and family history might help to identify vulnerability to bipolar disorders which could trigger further

diagnostic assessment, given the strong association between bipolar disorder and increased risk for PPDs<sup>141, 142</sup>.

In general, screening programs in the postpartum period should include a clear pathway from screening, to diagnostic assessment and treatment<sup>170</sup>. Best practice guidelines agree that all women who have a positive screen need subsequent assessment, during which, co-morbidities and the woman's wider psychosocial context can be explored. Currently, only such well-resourced, integrated management programs have provided evidence that perinatal mental health is improved by depression screening<sup>171, 172</sup>. In this regard, e-screening and e-treatments to facilitate integrated, cost-effective care might be useful<sup>173</sup>. Few well-understood, validated screening approaches for PPDs that can ultimately improve morbidity and mortality are available. Indeed, further building of the evidence-base for screening, including the cost-effectiveness of perinatal depression screening as a policy direction is required<sup>142, 174</sup>.

## **[H2] Prevention**

Interventions for the prevention of postpartum depression or postpartum anxiety are intended to prevent the onset, duration, or recurrence of these disorders. Prevention can reduce the mental health, physical health and socio-economic burden associated with postpartum depression for mothers, their offspring and families, as well as for health systems. The effectiveness of prevention of postpartum depression is facilitated by the fact that pregnant women are motivated to address factors that will affect their baby<sup>175</sup>. The assessment of risk factors for PPDs helps with diagnosis and formulation, but is also important for identifying potentially modifiable targets for prevention and treatment (**Box 3**)<sup>176</sup>. Thus, it is a requirement for both symptom screening and risk assessment that systems exist for adequate follow-up and support. Furthermore, women and clinicians should be informed that the established risk factors might have limited predictive value

570 for individual patients and, therefore, do not guarantee which women will develop or not develop  
571 postpartum depression.

572 Some psychosocial and psychological interventions have reduced the risk of women developing  
573 postpartum depression, although no single intervention type or modality appears superior to  
574 others. Data from trials included in a Cochrane review<sup>176</sup> as well as randomized controlled trials  
575 included in a qualitative review,<sup>175</sup> point towards particularly positive impacts when interventions  
576 target at-risk groups (such as women with a previous episode of depression or a recent life  
577 stressor), or include interpersonal therapy (IPT). As relationship challenges and lack of social  
578 support constitute strong risk factor for PPD, the interpersonal focus of the IPT intervention,  
579 therefore aims to address this causative or aggravating factor. Interventions with the most promise  
580 include interventions targeting at-risk groups (such as women with a previous episode of  
581 depression or a recent life stressor).

582 Trials included in these reviews were conducted among high risk women, based on various factors,  
583 as well as women enrolled from the general perinatal population. Trials assessing the use of  
584 interpersonal therapy, cognitive behavioural therapy, peer support, parental preparedness, and  
585 person-centred approaches for prevention of postpartum depression have demonstrated  
586 significantly positive results, whereas trials assessing the use of cognitive behavioural therapy for  
587 postpartum depression have demonstrated mixed results. These results, disaggregated for  
588 universal, selective or indicated prevention strategies are summarized in a more recent systematic  
589 review and meta-analysis<sup>177</sup>. The interventions were delivered using several modalities, including  
590 home visits and telephone support, provision by professional and lay practitioners, individual and  
591 group-based sessions, through multiple contact sessions and at postpartum initiation<sup>176</sup>.

592 There is conflicting evidence for the treatment of vulnerable women with antidepressants for the  
593 prevention of depressive episodes or anxiety symptoms during the perinatal period as well as  
594 anxiety symptoms has conflicting evidence <sup>178</sup>. One of the earliest studies demonstrated a



reduction in recurrence of postpartum major depression with prophylactic antidepressant treatment<sup>179</sup>. Small but emerging literature has suggested hormonal therapies, light therapy and other forms of circadian manipulation might be promising therapies for prevention of depression<sup>180</sup>. There is no strong evidence for the use of hormonal therapies, acupuncture, supplementation with omega-3 polyunsaturated fatty acids, light therapy and other forms of circadian manipulation for prevention of postpartum depression.<sup>177,180</sup>

Interventions for the prevention of postpartum psychosis include careful monitoring for symptom development in women at high risk and adjustments of prophylactic medication, especially in women with bipolar disorder<sup>18, 24</sup>. Prophylactic treatment during pregnancy might reduce the rate of postpartum relapse in women with bipolar disorder, although no evidence from randomized controlled trials for this is available. For women with previous postpartum psychosis, prophylactic treatment with lithium or antipsychotics immediately postpartum might reduce relapse<sup>18</sup>.

## **[H1] Management**

The goals of treating mental illness in the postpartum period are to reduce maternal psychiatric symptoms and to support maternal-child and family functioning. All women and their families should receive education about the illness and the potential treatment options, including the potential benefits and harms of each treatment option. Social support should be optimized and physical and psychiatric comorbidities should be addressed. In addition, strategies to assist women in obtaining sleep and a stable circadian rhythm are helpful, given that sleep deprivation is common during the postpartum period. In many cases, the symptoms of PPDs influence maternal-child interactions, which should be observed and discussed in a non-judgmental way.

Although specific recommended treatments depend on the underlying diagnosis, in general, a stepped care approach is advocated, in which the intensity of the intervention matches the severity and acuity of the clinical presentation. For example, women with mild symptoms of depressive,

anxiety, obsessive–compulsive and/or trauma or stressor-related disorders should first be offered the lowest-intensity interventions such as peer support and guided self-help, whereas women who do not respond to these treatments might require formal psychotherapeutic interventions, such as psychological therapies. For women with severe symptoms, who do not respond to non-pharmacological treatment, or who have bipolar disorder or psychosis, pharmacological interventions are likely to be introduced as a first-line treatment, used alone or in combination with a lower-intensity intervention. In such cases, the well-established benefits of breastfeeding on the infant must be considered in the context of maternal mental wellbeing, the passage of psychotropic medication into breast-milk and the infant, and the potential effects of medications on the neonate. Indeed, when breast-feeding is challenging, and/or when frequent nighttime feedings leads to sleep disruption, symptoms of depression or anxiety might be precipitated or exacerbated. In these cases, the benefits of breastfeeding must be weighed against the risk of ongoing maternal mental illness, and formula feeding is a viable and often recommended alternative. Other somatic treatments, such as electroconvulsive therapy (ECT), can be considered in women with treatment-refractory disorders. Throughout, monitoring progress to determine when or if to move to a higher-intensity intervention, and to ensure safety for mother and child is important. In the initial assessment and during treatment the patient and her family should be asked if thoughts of suicide or infanticide have occurred. Safety concerns and/or evidence of active psychosis are medical emergencies that require specialist consultation, emergency hospitalization and treatment.

## **[H2] Mood disorders and anxiety**

Treatment of postpartum depression and other non-psychotic mental disorders (such as anxiety, OCD and trauma and stressor-related disorders; **Box 4**) depends on the severity of the initial presentation and the level of functional impairment, including the effect on the maternal–child interaction.<sup>128</sup> For women with a past history of mental illness, the previous treatment response and the time to response of previous episodes should be considered. The patient's treatment

preference, in addition to as access to care and utilization of care should also be considered in all women, as patients who receive their preferred treatment are most likely to benefit from this treatment than other treatments.<sup>181</sup> Most women with non-psychotic mental disorders often prefer psychotherapy over pharmacological treatments, although the uptake and effectiveness of this therapy can be limited due to barriers in attending appointments, such as unpredictable infant schedules and competing childcare responsibilities.<sup>182</sup> Similarly, fathers also prefer psychological treatments to pharmacological therapy.<sup>183</sup> However, some women prefer pharmacological treatment alone, so individualizing treatments based on patient preferences is important. Treating maternal postpartum depression might not always improve the maternal–infant relationship, and additional interventions aimed at the mother–infant dyad or the family as a whole might be required.<sup>184</sup>

**[H3] Psychological Interventions.** Most trials for postpartum depression have focused on non-pharmacological treatments. For women with mild postpartum depression, psychosocial treatments including peer support, guided self-help, and supportive counseling by trained professions such as public health nurses (at home, or in support groups) can improve symptoms. For example, one systematic review of 5 trials demonstrated a 1 year remission rate of 68% in women with postpartum depression who received psychosocial treatments compared with a remission rate of 54% in women treated with standard primary care.<sup>185</sup> For women with moderate symptoms of depression, or women who do not responded to psychosocial strategies, psychotherapies such as cognitive-behaviour therapy (CBT) and interpersonal therapy (IPT) that specifically address the psychological and related challenges of transitioning to parenthood are effective when delivered in individual, group, and partner-assisted formats, and either in-person, by telephone, or online.<sup>186</sup> A systematic review of 4 CBT and 1 IPT trials demonstrated a pooled remission rate of 60.3% for these interventions, compared with a rate of 48.1% for usual care.<sup>185</sup>

In addition, a CBT-based program was demonstrated to reduce worry and depressive symptoms in women with postpartum anxiety disorders, including GAD, social phobia and OCD, compared with symptoms at baseline.<sup>187</sup> The effectiveness of CBT for postnatal OCD symptoms was confirmed in a small RCT.<sup>188</sup> Although additional research is required, CBT-based interventions for postpartum anxiety disorders, and specifically interventions such as eye movement desensitization and reprocessing (EMDR) and trauma-focused CBT for trauma and stressor related disorders, can be used, although the latter two interventions have not been specifically evaluated in postpartum women <sup>189</sup>.

The increasing use of internet-based CBT and the development of mobile apps that use this treatment modality demonstrates the power of digital health, which is often more accessible than traditional psychotherapy, and extends to individuals who can't participate in psychotherapy. A good example of this is MumMoodBooster, which was developed in Australia<sup>173</sup>.

**[H3] Drug therapies.** Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are the mainstay of pharmacological treatment for postpartum anxiety and depressive disorders. These therapies can be used alone or in combination with psychosocial or psychological treatments. In a systematic review, the pooled remission rate was significantly higher in patients receiving SSRIs (46.0%) compared with those receiving placebo (25.7%).<sup>190</sup> Although pharmacological therapies can be used alone or in combination with psychosocial or psychological treatments, whether combinatorial therapy is superior to either one alone has not been evaluated in postpartum women. However, combinatorial treatment does not lead to further improvements in functional outcomes compared with medication alone, in non-perinatal populations.<sup>191, 192</sup> To our knowledge, there are no drug treatment trials in maternal anxiety disorders, or in paternal postpartum depression or anxiety. However, SSRI and SNRI medications are first line pharmacological treatments for anxiety and depression outside the postpartum period. The duration of antidepressant therapy required for new-onset postpartum

depression, anxiety or a related disorder has not been studied, but clinicians are recommended to follow guidelines for these disorders in the general population. For depression, the initial treatment should be continued for 6 months to 1 year after remission; longer durations are required for severe and/or recurrent illness.<sup>193</sup>

Many women and their partners are concerned about the safety of using antidepressant drugs during breastfeeding. However, the use of antidepressants during the postpartum period is not a contraindication to breastfeeding, and indeed, the avoidance of medication when needed for severe illness is associated with maternal suicides<sup>194</sup>. The passage of SSRIs and SNRIs into breast-milk is variable between drugs, but most pass into the breast-milk at <10% of the maternal dose, which is compatible with breast-feeding.<sup>195</sup> As such, changing the antidepressant drug or the dose during the perinatal period to switch to a drug with lower breast-milk passage is generally not recommended. For new-onset postpartum depression, sertraline is often recommended as a first-line pharmacological treatment due to very minimal passage into breast-milk (Figure 2). However, in patients with a prior history of psychiatric disorders, therapies that have previously demonstrated efficacy should be considered, even those that have less data regarding safety during breastfeeding. Other SSRIs, SNRIs or mirtazapine (an atypical antidepressant) also have minimal passage into breast-milk, so these drugs are unlikely to be a cause for concern. Bupropion is generally not given to lactating women due to case reports of infant seizures associated with exposure to this drug.<sup>196</sup> In cases of severe depression and/or anxiety (with or without psychotic features), older antidepressants, other therapies such as benzodiazepines or antipsychotics might be indicated.

**[H3] Other treatments.** Given the likely role of hormonal fluctuations in the aetiology of postpartum depression, hormonal treatments have been evaluated. Transdermal oestrogen therapy reduced the symptoms of postpartum depression in one small study, but further trial are required. Progestin

therapy worsens postpartum depressive symptoms.<sup>197</sup> One trial of demonstrated the superiority of allopregnenalone to placebo in improving depressive symptoms in 21 women with severe postpartum depression,<sup>92</sup> although this requires further investigation. Complementary and alternative medicine treatments (for example, folate, s-adenosylmethionine, massage and acupuncture) are not well-supported by evidence.<sup>198</sup> However, using aerobic exercise for postpartum depression was recently examined in a systematic review and has good supporting evidence for mild symptomatology <sup>199</sup>. ECT can be considered in severe or treatment-refractory cases of depression.

## **[H2] Postpartum psychosis**

Fluctuations in symptoms are common in women with postpartum psychosis, and thoughts of infanticide or suicide are often well hidden. Thus, outpatient treatment is not safe and psychiatric hospitalization is recommended for diagnostic evaluation and treatment <sup>15</sup>. The preferred treatment setting is a mother–baby joint admission unit, but these units are not available worldwide <sup>200, 201</sup>. Alternatives are the admission of the mother only to a hospital with expertise in perinatal psychiatric care or women’s mental health, or, if these facilities are unavailable, admission to a standard mental health inpatient setting, or based on a careful assessment of the safety of both the mother and the infant, intensive home treatment where available and with appropriate supervision<sup>16</sup>. The effect of these approaches on long term outcomes of the mother and baby are being investigated<sup>15</sup>.

The management of postpartum psychosis is dependent on psychiatric history. For women with known severe psychiatric illness with non-perinatal episodes, reviewing the nature and effectiveness of past treatments and restarting previous effective treatment is important. Management of women without a history of bipolar disorder or other severe psychiatric disorder are summarized in Figure 2. The main treatment goals for women without a prior history of bipolar

disorder, psychosis or other severe psychiatric disorder include the limitation of the current episode and the prevention of a bipolar disease course with multiple episodes. Accordingly, management in the first year postpartum should focus on full recovery (that is, complete symptom remission and social and vocational functioning). In the absence of guidelines and controlled trials, treatment recommendations are based on results from naturalistic cohort studies and expert consensus groups<sup>24, 202</sup>. The largest study (consisting of 68 patients) demonstrated the efficacy of a stepwise sequence of short-term benzodiazepines, antipsychotics and lithium, and showed high remission rates (remission in 98.4% of women) in the acute phase<sup>203</sup>. Moreover, this study demonstrated that lithium monotherapy is protective against relapse of psychosis, depression and mania within one year. The second largest study described successful ECT treatment in 34 patients with postpartum psychosis of whom many had symptoms of catatonia<sup>204</sup>. The effectiveness of lithium and ECT is supported by case reports<sup>205</sup>. Successful treatment with antipsychotics has been described in case reports<sup>206, 207</sup>, but antipsychotic monotherapy did not show efficacy in a cohort study<sup>203</sup>. Together, lithium monotherapy might be the preferred initial intervention for postpartum psychosis but adjunctive treatment with benzodiazepines or antipsychotics is useful for the acute treatment of agitation, mania and psychotic symptoms, given the well documented effectiveness in non-perinatal populations. Several antipsychotics are used for the treatment of severe PPDs including risperidone, quetiapine and olanzapine<sup>208</sup>. ECT is the primary treatment for patients with severe catatonic or depressed psychotic features, or if patient's prefer this therapy<sup>15</sup>.

Anticonvulsants (that is, antiepileptic medications) are also used less frequently as mood stabilizers in the treatment of bipolar disorder because of concerns of teratogenicity. However, valproate use during pregnancy and lactation is associated with neural tube defects and neurocognitive developmental delays in the offspring<sup>24, 209</sup>. Thus, valproate use is not advised during the perinatal period, unless the risk/benefit assessment determines a prior efficacy in particular women. By contrast, lamotrigine is used for the treatment of bipolar–depression (not bipolar–mania) and is not associated with an increased risk of congenital malformations in

775 offspring.<sup>210</sup> A review of recent studies demonstrated that lamotrigine had no adverse outcomes  
776 on infant IQ or neurodevelopment.<sup>211</sup>

777 The management of a breastfeeding woman with a severe psychiatric episode is challenging  
778 due to concerns about the exposure of breastmilk to pharmacological therapies and the need  
779 for sleep preservation in the mother<sup>15</sup>. The use of lactation inhibitors should be avoided. In some  
780 countries, the mother is recommended to breastfeed only if extensive psychiatric support and  
781 access to a pediatric professional that can monitor the infant are available. Moreover, the mother  
782 and her partner should be educated about the risks of breastfeeding with pharmacotherapy. In  
783 other countries, a more individualized approach (for example, NICE guidelines) based on previous  
784 responses to medication, preferences regarding breastfeeding and psychopathology<sup>24</sup>, other than  
785 avoidance of breastfeeding if lithium (rather than an antipsychotic) is used. Small case series have  
786 provided information regarding the safety of lithium in lactation<sup>212, 213</sup>. When possible, level of  
787 lithium in the infants serum should be closely monitored; on average, the serum level of lithium is  
788 25% of the maternal levels, but the range can vary and dehydration can lead to toxic levels<sup>15,213</sup>.  
789 No adverse effects were reported in ten infants of breastfeeding mothers who received ECT<sup>204</sup>.

790

## 791 **[H1] Quality of life**

792 The symptoms and morbidity of postpartum depression are often reported in the academic  
793 literature, but this offers only a rather constricted view of the quality of life (QOL) of women with  
794 PPDs.<sup>125,214 215</sup> Nevertheless, the classic core symptoms of a depressive disorder would be  
795 expected to decrease the subjective quality of both an individual's inner life experience (anhedonia,  
796 sadness, hopelessness, thoughts of death), and their functioning (psychomotor retardation or  
797 agitation, disturbed sleep). Anxiety is frequently co-morbid and this further influences quality of life  
798 with persistent worry symptoms.



799 Definitions vary, but QoL is a broader multidimensional construct which commonly incorporates  
800 two central aspects: emotional well-being (including, frequency and intensity of joy, sadness,  
801 affection) and life evaluation (how satisfied one is with one's life, for example, housing,  
802 employment). Health, and the ability to function, as an essential component of QoL is referred to as  
803 health-related quality of life (HRQoL). Maternal QoL during the postpartum period also affects her  
804 infant's current and future quality of life. Many mothers with postpartum depression have difficulty  
805 interacting with their infants in a positive way<sup>216</sup>, such as making less eye contact, showing less  
806 synchronous responsiveness, being uninvolved and showing restricted affect during mother-infant  
807 interactions.<sup>217-219</sup> Infant attachment security is a key predictor of child outcomes, including  
808 neurological, psychological and social outcomes over the course of development<sup>220</sup>. In addition,  
809 children of mothers with perinatal depression might have poorer psychological outcomes when  
810 they reach 18 years of age<sup>221</sup>. Some women have an intrusive engagement style that might lead to  
811 long-term difficulties in child social, cognitive and behavioural domains<sup>222</sup>. Women with postpartum  
812 psychosis face even more many parenting challenges often including disrupted attachment, which  
813 impact on the quality of life for mother and child.<sup>223</sup>

814 One of the most widely used generic measures of QOL is the 36 item short-form (SF-36)<sup>224, 225</sup>,  
815 which has eight health domains that measure limitations in physical or usual role activities due to  
816 health issues, limitations in usual role or social activities due to emotional issues, pain, mental  
817 health, vitality, and general health perceptions. The SF-36 has been used in over 1,000  
818 publications and for over 130 disorders including those that occur during the postpartum period,  
819 and both the full and short versions of this scale have been validated by numerous studies<sup>225, 226</sup>.  
820 However, few measures of QOL have been developed specifically for use in the postpartum  
821 period<sup>227</sup>. Only <sup>228</sup> three instruments for use during the postpartum period were reported in one  
822 systematic review: The Mother-Generated Index (MGI)<sup>229</sup>, the Maternal Postpartum Quality of Life  
823 Questionnaire (MAPP-QOL)<sup>230</sup> and the Rural Postpartum QOL scale (RPQoL)<sup>231</sup>. The MGI requires  
824 women to specify domains of their life that have been affected by the birth of their baby, either

825 positive or negative, and to then score these out of 10.<sup>232</sup> The most common changes reported  
826 were tiredness, less personal time, less time with partner or other family members, a worse  
827 relationship with partner or other family members, physical complaints, low self-esteem, financial  
828 worries, negative feelings towards the baby, more housework, poor sex life, decreased pleasure  
829 from baby, less sense of happiness or fulfilment<sup>229</sup>.

830 Not surprisingly, people with depressive illness in general report lower scores on generic QoL and  
831 HRQoL measures, as do women experiencing postpartum depressed mood.<sup>233 234</sup> Small studies in  
832 postpartum women also suggest QoL is amenable to intervention. Improvements in QOL are not  
833 fully explained by improvements in the severity of depressive symptom suggesting that  
834 interventions should go beyond the mere reduction of symptom severity and consider other factors  
835 that contribute to QoL as targets for intervention. . Maternal-specific measures of QOL could be  
836 integrated into postpartum depression screening programs or routine postnatal care<sup>235, 236</sup>. Indeed,  
837 QoL measures that allow a women to identify which areas of her life are most important to her,  
838 could be used to allow women to indicate where she would like to see improvements.<sup>229</sup> Emerging  
839 studies have highlighted the beneficial effect of social support on QOL<sup>237</sup>, in addition to risk factors  
840 for reduced QOL such as younger age and lower socio-economic status in women with postpartum  
841 depression<sup>238</sup>.

842 PPDs have economic considerations and can affect quality-adjusted life years (QALY)<sup>142</sup>. QALY  
843 takes into account how treatment affects quality and quantity of life, and accordingly, QoL  
844 measurement is necessary for studies of cost-effectiveness of treatments. Compelling data from  
845 the London School of Economics<sup>239</sup> demonstrated the high economic costs of PPDs and the need  
846 to address the loss of QALYs of women and their children, by treatment and prevention of these  
847 disorders. This finding is particularly pertinent given the short and long-term effects of postpartum  
848 depression. Indeed, as most women recover from postpartum mood disorders, these disorders can  
849 become chronic in a subgroup of women<sup>240</sup>. One study demonstrated that, for each one-year

850 cohort of births, perinatal depression, anxiety and psychosis cost the UK around £8.1 billion in the  
851 long-term.<sup>239</sup>

852

## 853 **[H1] Outlook**

854 The postpartum period is a vulnerable time for onset of psychiatric illness. Indeed, postpartum mood  
855 and anxiety are heterogeneous and might be triggered by biopsychosocial factors including a  
856 vulnerability to the robust endocrine and immune-related changes that occur at childbirth. The  
857 heterogeneity of these disorders requires a thoughtful approach to assessment and treatment  
858 planning that includes the clinical presentation, family and personal psychiatric history, other  
859 psychosocial risk factors (including history of trauma), and awareness of potential biological or  
860 genetic contributions that might influence risk and vulnerability.

861 The precise vulnerability that leads to some women developing PPDs is currently unknown and novel  
862 research approaches are needed to identify the underlying pathophysiology of both prepartum and  
863 postpartum anxiety, depression and psychosis. This will require a multi-faceted approach in  
864 preclinical, clinical and translational research, to determine the mechanisms behind the neurobiology  
865 and physiological correlates of PPDs, and the observed peripartum mood and mothering behaviors.  
866 Additionally, these strategies must address the differences in the timing of symptom onset and the  
867 diverse types of symptoms.

868 Given the morbidity and mortality of postpartum psychosis, episodes of psychosis might be best  
869 considered to represent women with a bipolar disorder diathesis with a puerperal trigger.

870 Understanding this trigger will be beneficial and should allow the development of new treatments  
871 and, ultimately, enable the prevention of psychosis or prevent unfavourable outcomes in women at  
872 high risk. Effective evidence based treatment approaches are available for psychosis and  
873 depression, including psychopharmacology, psychotherapy and ECT and circadian manipulation.

874 However, postpartum depression and postpartum psychosis require different and targeted

875 treatment approaches and therefore, bipolarity must be considered in the evaluation and  
876 management of all women with postpartum mood and anxiety disorders. In addition, primary  
877 treatment goals should include the limitation of the current episode and the prevention of future  
878 episodes (including unipolar or bipolar disease with multiple episodes, and chronic anxiety).  
879 Whether there a continuum of severity between postpartum depression and postpartum psychosis,  
880 or whether these disorders represent different conditions with different aetiological factors requires  
881 further study.

882 A potential barrier to the engagement and retention of women in the treatment of postpartum mood  
883 disorders is stigma. Understand this stigma and the fear that women have regarding postpartum  
884 mood disorders is essential. The voices of women with postpartum mood disorders must be  
885 incorporated into the development of services to ensure the needs of women, their infants and  
886 families are met<sup>241, 242</sup>.

887 To date, the amount of research provides an important road map for PPDs in general, and  
888 guidelines for screening or identification and treatment for perinatal depression in many countries  
889 gives a strong mandate to improve mental health care for all women in the perinatal period. Thus,  
890 developing effective strategies in low, middle and high income countries that allow the delivery of  
891 targeted therapies to women with different clinical phenotypes and severity of PPDs is imperative.  
892 In addition, whether the current ICD-10 and DSM-5 classification systems are adequate for  
893 detecting specific phenotypes or diagnostic groups of patients should be evaluated. We should  
894 also consider that PPDs might be phenotypically different than psychiatric disorders that begin  
895 during pregnancy. Indeed, disorders that occur postpartum might have unique characteristics in  
896 epidemiology, pathophysiology, psychosocial contributions, prevention and management than  
897 disorders that occur during pregnancy.

898 In summary, PPDs are morbid and costly disorders. Advocating for early identification and  
899 screening that begins in pregnancy to identify women at risk, in addition to timely and effective

treatments of PPDs is essential. Given the recent advances in knowledge, this an incredibly exciting time for research in perinatal mood disorders. New approaches might allow the identification of the underlying causes of postpartum mood disorders, which could lead efforts to identify women at risk and personalize treatment. Although genetic, biological and hormonal signals likely have an important role in risk of these disorders, psychosocial contributions including the current impact of lifetime stressors must be part of comprehensive work-up and treatment plan. The social determinants of postpartum mood disorders, such as poverty, domestic violence, poor housing, and insecure migrant status, should also be assessed as part of routine practice of maternal health care for all women. Finally, we must recognize that maternal mental health is necessary for the physical and mental health of mothers, infants and families<sup>17</sup> and advocating and protecting this population is our obligation.

913 **Display items**

914

915 **Box 1. Paternal postpartum depression.**

916 Fathers can also experience depression after the birth of a child. Indeed, in men, the prevalence of  
917 depression after the birth of a child is greater than at other times during life<sup>243</sup>. Although the  
918 literature of paternal depression is much smaller than that for maternal depression, the available  
919 literature demonstrates that paternal depression increases the risk for long-term adverse outcomes  
920 in the child due to potential impairments in parenting<sup>244, 245</sup>. In addition, a strong link between  
921 maternal depression and paternal depression has been reported. Pregnant women who had  
922 partners with depression during their pregnancy had worse depression symptom severity during  
923 the first six months postpartum<sup>246</sup>. Thus, including fathers in health assessments during the  
924 postpartum period and screening fathers for postpartum psychiatric disorders at similar time  
925 intervals as maternal screening is important. Efforts aiming to improve the overall health and  
926 functioning of the family unit will lead to best outcomes for the child<sup>243, 245</sup>.

927

928

929

## **Box 2. Postpartum mental illness in low-income and middle-income countries**

In resource-poor settings, women of reproductive age typically have socio-economic and health challenges that interplay in mutually reinforcing ways.<sup>247, 248</sup> For example, low levels of education, low gender status, food insecurity, domestic abuse and lack of access to social and health services leave women and girls vulnerable to maternal mortality and chronic morbidities, including common mental health disorders.<sup>249, 250</sup> Indeed, the prevalence of common perinatal mental disorders in low- and lower-middle-income countries is higher than in high-income countries. One systematic review and meta-analysis<sup>21</sup> demonstrated a weighted mean prevalence of 15.6% in pregnant women and 19.8% in women after childbirth. The most strongly associated factors for perinatal mental disorders are socio-economic disadvantage, unintended pregnancy, younger age, unmarried status, lacking intimate partner empathy and support, hostile in-laws, partner violence, insufficient emotional and practical support, a history of mental health problems and in certain settings, a female infant.<sup>21</sup>

### **[H1] Considerations for management**

Mental health prevention and treatment investments in high-income countries is more than US\$50 per year per person, compared with less than US\$2 in most LMIC,<sup>251</sup> resulting in a profound paucity of mental health providers in these settings. The intervention coverage for common mental disorders (including those that occur during the perinatal period) ranges from 7% to 28% in LMICs.<sup>252</sup> The low monetary allocation represents, in part, poor appreciation by decision makers of the effect of mental illness on population disability and socio-economic development, low levels of political will and capacity, and competing health and development priorities.<sup>253</sup> Interventions that are most likely to succeed in LMICs would, therefore, need to adopt a systems strengthening, integrated and low-cost approach. Examples showing promise have integrated mental health into primary care, maternal and child health services or into the routine community based delivery of

health services (carried out by trained lay workers, or primary care healthworkers, using a task-sharing approach)<sup>254</sup>. Emerging evidence supports the benefit of including poverty alleviation strategies in to mental health interventions.<sup>255</sup>

## **[H1] Types of interventions**

A systematic review and meta-analysis of evidence of common perinatal mental disorder trials from LMIC, reported similar relative risk outcomes in studies carried out in high-income countries<sup>256</sup>. For the 13 trials selected, the pooled effect size for maternal depression was -0.38. In this review, trials that demonstrated positive results used several culturally adapted treatment paradigms, either singly or in combination. The Thinking Health Program in Pakistan was a cognitive behaviour therapy (CBT) intervention delivered in homes in a semi-rural setting by Lady Health Workers.<sup>257</sup> Uptake of the intervention leveraged the belief, within multi-generational households, that the intervention with the mother would improve the infant's well-being . In an urban, deprived setting in Chile, midwives and nurses were trained to deliver eight weekly structured psychoeducational group sessions. These sessions included information about symptoms and treatments, some problem solving strategies, behavioural activation strategies (such as scheduling pleasurable activities) and some cognitive techniques using postnatal examples <sup>258</sup> .

Subsequently, a trial in Zimbabwe <sup>259</sup> used peer counsellors to deliver six weeks of group problem solving therapy adapted for the local setting to postnatal women with depression. In this study, family members were co-opted to support the mothers through strategies identified in the problem solving and a specific treatment element that explored community resources and support systems was included. Six weeks after the intervention, the drop in mean EPDS score was greater in the PST group than the control group who received antidepressant therapy. No difference in outcomes between women with or without HIV was reported.



**Box 3. Targeting risk factors for postpartum depression.**

Assessing the common psychosocial risk factors for postpartum depression might have the following functions:

- Assisting in the initiation of targeted interventions or determining rational management decisions to mitigate the risks across several global settings through
  - risk reduction interventions (for example, referring women for social grants, to domestic violence support groups or to a women's shelter and provision of integrated interventions for the mood disorder, which also addresses domestic violence<sup>260</sup>
  - activation of protective factors, (such as interpersonal therapy for relationship difficulties or activating social support networks)<sup>175, 260</sup>.
- Assisting in screening of women who have an increased risk of postpartum depression but do not currently have the disorder.
- Assisting in timely referral for support in women with suspected postpartum depression and complicated psychosocial risk factors who are reluctant to endorse symptoms during screening due to stigma and poor contextual validity of the screening tool in some global settings, among other reasons<sup>261</sup>. This approach acknowledges that there may be several contextual factors contributing to false negative mental health screening results.

1000 **Box 4. General management guidelines for non-psychotic psychiatric disorders**

- 1001 1. Identify somatic comorbidities and optimize their management.
- 1002 2. Check the mode of delivery, if complications were present and if delivery was experienced
- 1003 as traumatic. In the case of post-traumatic stress symptoms, consider specific treatments.
- 1004 3. Assess for suicidal thoughts and intrusive thoughts of harm toward the baby. Consider the
- 1005 safety of the baby and whether the mother can provide care for the baby if she is alone or if
- 1006 other adult supervision is required.
- 1007 4. Ask the mother of her attitude towards her baby and observe maternal-child interactions.
- 1008 Consider specific treatments with signs of problematic interactions or bonding.
- 1009 5. Review the feeding pattern of the baby. Address problems with breast or bottle-feeding.
- 1010 6. Provide strategies to preserve sleep, such as finding another person to feed the infant at
- 1011 night.
- 1012 7. Assess psychiatric history before delivery. Review the nature and effectiveness of past
- 1013 treatments, and restart previous effective treatment when appropriate.

1014

1015

1016

1017 **Figure 1, Mechanisms of postpartum psychiatric disorders.**

1018 Several factors have been implicated in the aetiology of postpartum psychiatric disorders, including  
1019 both postpartum depression and postpartum psychosis. These factors include psycho-social  
1020 factors and biological factors that are specific to pregnancy and the postpartum period, such as  
1021 drastic alterations in gonadal sex steroids and impaired mother-infant interactions. Whether the  
1022 aetiology of psychiatric disorders occurring in prenatally, during pregnancy or during the  
1023 postpartum period is different requires future study.

1024

1025 **Figure 2. Management of first onset postpartum psychiatric disorders.**

1026 Management of postpartum psychiatric disorders should take into account the diagnosis (such as  
1027 psychosis, anxiety or depression), symptom severity and, with regards to mood and anxiety  
1028 disorders, whether the mother is breastfeeding.

1029

1030 **Bibliography: [Au: There are 5 pairs of duplicated references, can you please fix these using**  
 1031 **your reference manager:-- YES, this has been fixed. Thanks for letting me know!**

- 1032 • 27 and 147-- corrected
- 1033 • 16 and 19-- corrected
- 1034 • 30 and 162-- corrected
- 1035 • 11 and 22—corrected.
- 1036 • 20 and 56] --corrected

- 1037 1. Munk-Olsen, T., Laursen, T.M., Pedersen, C.B., Mors, O. & Mortensen, P.B. New parents and  
 1038 mental disorders: a population-based register study. *The journal of the American Medical*  
 1039 *Association* **296**, 2582-2589 (2006).
- 1040 2. Howard LM, R.E., Trevillion K, Anderson F, Bick D, Bye A, Byford S, O'Connor S, sands P,  
 1041 Demilew J, Milgrom J, Pickles P. . The accuracy of the Whooley questions and the Edinburgh  
 1042 Postnatal Depression Scale in identifying mental disorders in early pregnancy. *British Journal*  
 1043 *of Psychiatry* (in press).
- 1044 3. Heron, J., O'Connor, T.G., Evans, J., Golding, J. & Glover, V. The course of anxiety and depression  
 1045 through pregnancy and the postpartum in a community sample. *Journal of affective disorders*  
 1046 **80**, 65-73 (2004).
- 1047 4. Guintivano, J. et al. Adverse life events, psychiatric history, and biological predictors of  
 1048 postpartum depression in an ethnically diverse sample of postpartum women. *Psychol Med*, 1-  
 1049 14 (2017).
- 1050 5. Perry, A. et al. Adverse childhood life events and postpartum psychosis in bipolar disorder. *J*  
 1051 *Affect Disord* **205**, 69-72 (2016).
- 1052 6. Sawyer, A., Ayers, S. & Smith, H. Pre- and postnatal psychological wellbeing in Africa: a  
 1053 systematic review. *J Affect Disord* **123**, 17-29 (2010).
- 1054 7. Johannsen, B.M. et al. All-Cause Mortality in Women With Severe Postpartum Psychiatric  
 1055 Disorders. *Am J Psychiatry* **173**, 635-42 (2016).
- 1056 8. Gaynes, B.N. et al. Perinatal depression: prevalence, screening accuracy, and screening  
 1057 outcomes. *Evid Rep Technol Assess (Summ)*, 1-8 (2005).
- 1058 9. Chesney, E., Goodwin, G.M. & Fazel, S. Risks of all-cause and suicide mortality in mental  
 1059 disorders: a meta-review. *World Psychiatry* **13**, 153-60 (2014).
- 1060 10. Parsons, C.E., Young, K.S., Rochat, T.J., Kringelbach, M.L. & Stein, A. Postnatal depression and its  
 1061 effects on child development: a review of evidence from low- and middle-income countries. *Br*  
 1062 *Med Bull* **101**, 57-79 (2012).
- 1063 11. Gavin, N.I. et al. Perinatal depression: a systematic review of prevalence and incidence. *Obstet*  
 1064 *Gynecol* **106**, 1071-83 (2005).
- 1065 12. Meltzer-Brody, S. New insights into perinatal depression: pathogenesis and treatment during  
 1066 pregnancy and postpartum. *Dialogues Clin Neurosci* **13**, 89-100 (2011).
- 1067 13. Meltzer-Brody, S. & Stringer, E.M. Global maternal, newborn, and child health. *N Engl J Med*  
 1068 **370**, 1072 (2014).
- 1069 14. Norhayati, M.N., Hazlina, N.H., Asrenee, A.R. & Emilin, W.M. Magnitude and risk factors for  
 1070 postpartum symptoms: a literature review. *J Affect Disord* **175**, 34-52 (2015).
- 1071 15. Bergink, V., Rasgon, N. & Wisner, K.L. Postpartum Psychosis: Madness, Mania, and Melancholia  
 1072 in Motherhood. *Am J Psychiatry* **173**, 1179-1188 (2016).
- 1073 16. Jones, I., Chandra, P.S., Dazzan, P. & Howard, L.M. Bipolar disorder, affective psychosis, and  
 1074 schizophrenia in pregnancy and the post-partum period. *Lancet* **384**, 1789-99 (2014).
- 1075 17. Howard, L.M. et al. Non-psychotic mental disorders in the perinatal period. *Lancet* **384**, 1775-  
 1076 88 (2014).

- 1077 18. Wesseloo, R. et al. Risk of Postpartum Relapse in Bipolar Disorder and Postpartum Psychosis: A  
1078 Systematic Review and Meta-Analysis. *Am J Psychiatry* **173**, 117-27 (2016).
- 1079 19. Stewart, D.E. & Vigod, S. Postpartum Depression. *N Engl J Med* **375**, 2177-2186 (2016).
- 1080 20. Munk-Olsen, T. et al. Perinatal psychiatric episodes: a population-based study on treatment  
1081 incidence and prevalence. *Transl Psychiatry* **6**, e919 (2016).
- 1082 21. Fisher, J. et al. Prevalence and determinants of common perinatal mental disorders in women  
1083 in low- and lower-middle-income countries: a systematic review. *Bull World Health Organ* **90**,  
1084 139G-149G (2012).
- 1085 22. Franko, D.L. et al. Pregnancy complications and neonatal outcomes in women with eating  
1086 disorders. *Am J Psychiatry* **158**, 1461-6 (2001).
- 1087 23. Cox, J.L., Holden, J.M. & Sagovsky, R. Detection of postnatal depression. Development of the 10-  
1088 item Edinburgh Postnatal Depression Scale. *Br.J.Psychiatry* **150**, 782-786 (1987).
- 1089 24. Excellence, N.N.I.f.H.a.C. in The British Psychological Society and the Royal College of  
1090 Psychiatrists (London, United Kingdom, 2014).
- 1091 25. O'Connor, E., Rossom, R.C., Henninger, M., Groom, H.C. & Burda, B.U. Primary Care Screening for  
1092 and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report and  
1093 Systematic Review for the US Preventive Services Task Force. *JAMA* **315**, 388-406 (2016).
- 1094 26. Liu, X. et al. Depression and Anxiety in the Postpartum Period and Risk of Bipolar Disorder: A  
1095 Danish Nationwide Register-Based Cohort Study. *J Clin Psychiatry* **78**, e469-e476 (2017).
- 1096 27. Sharma, V., Doobay, M. & Baczynski, C. Bipolar postpartum depression: An update and  
1097 recommendations. *J Affect Disord* **219**, 105-111 (2017).
- 1098 28. Dennis, C.L., Falah-Hassani, K. & Shiri, R. Prevalence of antenatal and postnatal anxiety:  
1099 systematic review and meta-analysis. *Br J Psychiatry* **210**, 315-323 (2017).
- 1100 29. Munk-Olsen, T., Laursen, T.M., Pedersen, C.B., Mors, O. & Mortensen, P.B. New Parents and  
1101 Mental Disorders. A Population-Based Register Study. *JAMA* **296**, 2582-2589 (2006).
- 1102 30. Harlow, B.L. et al. Incidence of hospitalization for postpartum psychotic and bipolar episodes in  
1103 women with and without prior pre-pregnancy or prenatal psychiatric hospitalizations.  
1104 *Arch.Gen.Psychiatry* **64**, 42-48 (2007).
- 1105 31. Kendell, R.E., Chalmers, J.C. & Platz, C. Epidemiology of puerperal psychoses. *Br.J.Psychiatry*  
1106 **150**, 662-673 (1987).
- 1107 32. Valdimarsdottir, U., Hultman, C.M., Harlow, B., Cnattingius, S. & Sparen, P. Psychotic illness in  
1108 first-time mothers with no previous psychiatric hospitalizations: a population-based study.  
1109 *PLoS.Med.* **6**, e13 (2009).
- 1110 33. Bergink, V., Boyce, P. & Munk-Olsen, T. Postpartum psychosis: a valuable misnomer. *Aust N Z J*  
1111 *Psychiatry* **49**, 102-3 (2015).
- 1112 34. Di Florio, A. et al. Perinatal episodes across the mood disorder spectrum. *Journal of the*  
1113 *American Medical Association: Psychiatry* **70**, 168-75 (2013).
- 1114 35. Munk-Olsen, T. et al. Risks and predictors of readmission for a mental disorder during the  
1115 postpartum period. *Archives of general psychiatry* **66**, 189-95 (2009).
- 1116 36. Florio, A.D., Munk-Olsen, T. & Bergink, V. The birth of a psychiatric orphan disorder:  
1117 postpartum psychosis. *Lancet Psychiatry* **3**, 502 (2016).
- 1118 37. Lysell, H. et al. Maternal suicide - Register based study of all suicides occurring after delivery in  
1119 Sweden 1974-2009. *PLoS One* **13**, e0190133 (2018).
- 1120 38. Grigoriadis, S. et al. Perinatal suicide in Ontario, Canada: a 15-year population-based study.  
1121 *CMAJ* **189**, E1085-E1092 (2017).
- 1122 39. Kimmel, M. et al. Family history, not lack of medication use, is associated with the development  
1123 of postpartum depression in a high-risk sample. *Arch Womens Ment Health* (2014).
- 1124 40. Viguera, A.C. et al. Risk of recurrence in women with bipolar disorder during pregnancy:  
1125 prospective study of mood stabilizer discontinuation. *Am J Psychiatry* **164**, 1817-24; quiz 1923  
1126 (2007).

- 1127 41. Fonagy, P., Sled, M. & Baradon, T. Randomized Controlled Trial of Parent-Infant  
1128 Psychotherapy for Parents with Mental Health Problems and Young Infants. *Infant Ment Health*  
1129 *J* **37**, 97-114 (2016).
- 1130 42. Stein, A. et al. Effects of perinatal mental disorders on the fetus and child. *Lancet* **384**, 1800-19  
1131 (2014).
- 1132 43. Faisal-Cury, A., Menezes, P.R., d'Oliveira, A.F., Schraiber, L.B. & Lopes, C.S. Temporal  
1133 relationship between intimate partner violence and postpartum depression in a sample of low  
1134 income women. *Matern Child Health J* **17**, 1297-303 (2013).
- 1135 44. Onoye, J.M., Goebert, D., Morland, L., Matsu, C. & Wright, T. PTSD and postpartum mental health  
1136 in a sample of Caucasian, Asian, and Pacific Islander women. *Arch Womens Ment Health* **12**,  
1137 393-400 (2009).
- 1138 45. Gonzalez, A., Jenkins, J.M., Steiner, M. & Fleming, A.S. Maternal early life experiences and  
1139 parenting: the mediating role of cortisol and executive function. *J Am Acad Child Adolesc*  
1140 *Psychiatry* **51**, 673-82 (2012).
- 1141 46. Hipwell, A.E., Goossens, F.A., Melhuish, E.C. & Kumar, R. Severe maternal psychopathology and  
1142 infant-mother attachment. *Development and psychopathology* **12**, 157-75 (2000).
- 1143 47. Goodman, S.H. et al. Maternal depression and child psychopathology: a meta-analytic review.  
1144 *Clin Child Fam Psychol Rev* **14**, 1-27 (2011).
- 1145 48. Muzik, M. et al. Psychopathology and parenting: An examination of perceived and observed  
1146 parenting in mothers with depression and PTSD. *J Affect Disord* **207**, 242-250 (2017).
- 1147 49. Yim, I.S., Tanner Stapleton, L.R., Guardino, C.M., Hahn-Holbrook, J. & Dunkel Schetter, C.  
1148 Biological and psychosocial predictors of postpartum depression: systematic review and call  
1149 for integration. *Annu Rev Clin Psychol* **11**, 99-137 (2015).
- 1150 50. Xie, R.H. et al. Prenatal family support, postnatal family support and postpartum depression.  
1151 *Aust N Z J Obstet Gynaecol* **50**, 340-5 (2010).
- 1152 51. Rogathi, J.J. et al. Postpartum depression among women who have experienced intimate  
1153 partner violence: A prospective cohort study at Moshi, Tanzania. *J Affect Disord* **218**, 238-245  
1154 (2017).
- 1155 52. Fiala, A., Svancara, J., Klanova, J. & Kasparek, T. Sociodemographic and delivery risk factors for  
1156 developing postpartum depression in a sample of 3233 mothers from the Czech ELSPAC study.  
1157 *BMC Psychiatry* **17**, 104 (2017).
- 1158 53. Craddock, N. & Forty, L. Genetics of affective (mood) disorders. *Eur J Hum Genet* **14**, 660-8  
1159 (2006).
- 1160 54. Lichtenstein, P. et al. Common genetic determinants of schizophrenia and bipolar disorder in  
1161 Swedish families: a population-based study. *Lancet* **373**, 234-9 (2009).
- 1162 55. Byrne, E.M. et al. Applying polygenic risk scores to postpartum depression. *Arch Womens Ment*  
1163 *Health* (2014).
- 1164 56. Forty, L. et al. Familiality of postpartum depression in unipolar disorder: results of a family  
1165 study. *The American Journal of Psychiatry* **163**, 1549-1553 (2006).
- 1166 57. Mahon, P.B. et al. Genome-wide linkage and follow-up association study of postpartum mood  
1167 symptoms. *The American journal of psychiatry* **166**, 1229-37 (2009).
- 1168 58. Treloar, S.A., Martin, N.G., Bucholz, K.K., Madden, P.A. & Heath, A.C. Genetic influences on post-  
1169 natal depressive symptoms: findings from an Australian twin sample. *Psychol Med* **29**, 645-54  
1170 (1999).
- 1171 59. Viktorin, A. et al. Heritability of Perinatal Depression and Genetic Overlap With Nonperinatal  
1172 Depression. *Am J Psychiatry*, appiajp201515010085 (2015).
- 1173 60. Jones, I. et al. Bipolar affective puerperal psychosis: genome-wide significant evidence for  
1174 linkage to chromosome 16. *The American Journal of Psychiatry* **164**, 1099-1104 (2007).
- 1175 61. Jones, I., Craddock, N., Jones, I. & Craddock, N. Searching for the puerperal trigger: molecular  
1176 genetic studies of bipolar affective puerperal psychosis. *Psychopharmacology Bulletin* **40**, 115-  
1177 28 (2007).

- 1178 62. Consortium, P.D.A.T.C.a.T.P. Heterogeneity of postpartum depression: a latent class analysis.  
1179 *Lancet Psychiatry* **2**, 59-67 (2015).
- 1180 63. Putnam, K.T. et al. Clinical phenotypes of perinatal depression and time of symptom onset:  
1181 analysis of data from an international consortium. *Lancet Psychiatry* **4**, 477-485 (2017).
- 1182 64. Geronimus, A.T., Hicken, M., Keene, D. & Bound, J. "Weathering" and age patterns of allostatic  
1183 load scores among blacks and whites in the United States. *Am J Public Health* **96**, 826-33  
1184 (2006).
- 1185 65. Perroud, N. et al. Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with  
1186 a history of childhood maltreatment: a link with the severity and type of trauma. *Transl*  
1187 *Psychiatry* **1**, e59 (2011).
- 1188 66. Schwaiger, M. et al. Altered Stress-Induced Regulation of Genes in Monocytes in Adults with a  
1189 History of Childhood Adversity. *Neuropsychopharmacology* **41**, 2530-40 (2016).
- 1190 67. Vincent, J. et al. Assessing the contributions of childhood maltreatment subtypes and  
1191 depression case-control status on telomere length reveals a specific role of physical neglect. *J*  
1192 *Affect Disord* **213**, 16-22 (2017).
- 1193 68. Mitchell, A.M., Kowalsky, J.M., Epel, E.S., Lin, J. & Christian, L.M. Childhood adversity, social  
1194 support, and telomere length among perinatal women. *Psychoneuroendocrinology* **87**, 43-52  
1195 (2017).
- 1196 69. Osborne, L. et al. Replication of Epigenetic Postpartum Depression Biomarkers and Variation  
1197 with Hormone Levels. *Neuropsychopharmacology* **41**, 1648-58 (2016).
- 1198 70. Guintivano, J., Arad, M., Gould, T.D., Payne, J.L. & Kaminsky, Z.A. Antenatal prediction of  
1199 postpartum depression with blood DNA methylation biomarkers. *Mol Psychiatry* **19**, 560-7  
1200 (2014).
- 1201 71. Murray, G. & Harvey, A. Circadian rhythms and sleep in bipolar disorder. *Bipolar Disord* **12**,  
1202 459-72 (2010).
- 1203 72. Lewis, K.J., Foster, R.G. & Jones, I.R. Is sleep disruption a trigger for postpartum psychosis? *Br J*  
1204 *Psychiatry* **208**, 409-11 (2016).
- 1205 73. Marques, M. et al. Is insomnia in late pregnancy a risk factor for postpartum  
1206 depression/depressive symptomatology? *Psychiatry Res* **186**, 272-80 (2011).
- 1207 74. Parry, B.L. et al. Plasma melatonin circadian rhythm disturbances during pregnancy and  
1208 postpartum in depressed women and women with personal or family histories of depression.  
1209 *Am J Psychiatry* **165**, 1551-8 (2008).
- 1210 75. Thomas, K.A. & Burr, R.L. Melatonin level and pattern in postpartum versus nonpregnant  
1211 nulliparous women. *J Obstet Gynecol Neonatal Nurs* **35**, 608-15 (2006).
- 1212 76. Sharkey, K.M., Pearlstein, T.B. & Carskadon, M.A. Circadian phase shifts and mood across the  
1213 perinatal period in women with a history of major depressive disorder: A preliminary  
1214 communication. *Journal of Affective Disorders* **150**, 1103-1108 (2013).
- 1215 77. Bloch, M. et al. Effects of gonadal steroids in women with a history of postpartum depression.  
1216 *The American Journal of Psychiatry* **157**, 924-30 (2000).
- 1217 78. Sohrabji, F., Miranda, R.C. & Toran-Allerand, C.D. Estrogen differentially regulates estrogen and  
1218 nerve growth factor receptor mRNAs in adult sensory neurons. *J Neurosci* **14**, 459-71 (1994).
- 1219 79. Shimizu, E. et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in  
1220 depressed patients with or without antidepressants. *Biol Psychiatry* **54**, 70-5 (2003).
- 1221 80. Finocchi, C. & Ferrari, M. Female reproductive steroids and neuronal excitability. *Neurol Sci* **32**  
1222 **Suppl 1**, S31-5 (2011).
- 1223 81. Pluchino, N. et al. Steroid hormones and BDNF. *Neuroscience* **239**, 271-9 (2013).
- 1224 82. Epperson, C.N. et al. Preliminary evidence of reduced occipital GABA concentrations in  
1225 puerperal women: a 1H-MRS study. *Psychopharmacology (Berl)* **186**, 425-33 (2006).
- 1226 83. Schiller, C.E., Meltzer-Brody, S. & Rubinow, D.R. The role of reproductive hormones in  
1227 postpartum depression. *CNS Spectr* **20**, 48-59 (2015).
- 1228 84. Paul, S.M. & Purdy, R.H. Neuroactive steroids. *FASEB J* **6**, 2311-22 (1992).

- 1229 85. Majewska, M.D., Harrison, N.L., Schwartz, R.D., Barker, J.L. & Paul, S.M. Steroid hormone  
1230 metabolites are barbiturate-like modulators of the GABA receptor. *Science* **232**, 1004-7 (1986).
- 1231 86. Deligiannidis, K.M. et al. Peripartum neuroactive steroid and gamma-aminobutyric acid profiles  
1232 in women at-risk for postpartum depression. *Psychoneuroendocrinology* **70**, 98-107 (2016).
- 1233 87. Luisi, S. et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at  
1234 delivery, and in hypertensive patients. *J Clin Endocrinol Metab* **85**, 2429-33 (2000).
- 1235 88. Nappi, R.E. et al. Serum allopregnanolone in women with postpartum "blues". *Obstet Gynecol*  
1236 **97**, 77-80 (2001).
- 1237 89. Maguire, J., Mody, I., Maguire, J. & Mody, I. GABA(A)R plasticity during pregnancy: relevance to  
1238 postpartum depression. *Neuron* **59**, 207-13 (2008).
- 1239 90. Paoletti, A.M. et al. Observational study on the stability of the psychological status during  
1240 normal pregnancy and increased blood levels of neuroactive steroids with GABA-A receptor  
1241 agonist activity. *Psychoneuroendocrinology* **31**, 485-92 (2006).
- 1242 91. Kanes, S.J. et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe  
1243 postpartum depression. *Hum Psychopharmacol* **32** (2017).
- 1244 92. Kanes, S. et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised  
1245 controlled trial. *Lancet* **390**, 480-489 (2017).
- 1246 93. Algae, S.B. & Way, B.M. Evidence for a role of the oxytocin system, indexed by genetic variation  
1247 in CD38, in the social bonding effects of expressed gratitude. *Soc Cogn Affect Neurosci* **9**, 1855-  
1248 61 (2014).
- 1249 94. Cox, E.Q. et al. Oxytocin and HPA stress axis reactivity in postpartum women.  
1250 *Psychoneuroendocrinology* **55**, 164-72 (2015).
- 1251 95. Zelkowitz, P. et al. Psychosocial stress moderates the relationships between oxytocin, perinatal  
1252 depression, and maternal behavior. *Horm Behav* **66**, 351-60 (2014).
- 1253 96. Wei, S.M. et al. Brain-derived neurotrophic factor Val66Met genotype and ovarian steroids  
1254 interactively modulate working memory-related hippocampal function in women: a  
1255 multimodal neuroimaging study. *Mol Psychiatry* (2017).
- 1256 97. Sacher, J. et al. Relationship of monoamine oxidase-A distribution volume to postpartum  
1257 depression and postpartum crying. *Neuropsychopharmacology* **40**, 429-35 (2015).
- 1258 98. Wonch, K.E. et al. Postpartum depression and brain response to infants: Differential amygdala  
1259 response and connectivity. *Soc Neurosci* **11**, 600-17 (2016).
- 1260 99. Musser, E.D., Kaiser-Laurent, H. & Ablow, J.C. The neural correlates of maternal sensitivity: an  
1261 fMRI study. *Dev Cogn Neurosci* **2**, 428-36 (2012).
- 1262 100. Pawluski, J.L., Lonstein, J.S. & Fleming, A.S. The Neurobiology of Postpartum Anxiety and  
1263 Depression. *Trends Neurosci* **40**, 106-120 (2017).
- 1264 101. Roomruangwong, C. et al. A neuro-immune, neuro-oxidative and neuro-nitrosative model of  
1265 prenatal and postpartum depression. *Prog Neuropsychopharmacol Biol Psychiatry* (2017).
- 1266 102. Glynn, L.M., Davis, E.P. & Sandman, C.A. New insights into the role of perinatal HPA-axis  
1267 dysregulation in postpartum depression. *Neuropeptides* **47**, 363-70 (2013).
- 1268 103. Ferguson, E.H. et al. HPA axis reactivity to pharmacologic and psychological stressors in  
1269 euthymic women with histories of postpartum versus major depression. *Arch Womens Ment*  
1270 *Health* **20**, 411-420 (2017).
- 1271 104. Iliadis, S.I. et al. Associations between a polymorphism in the hydroxysteroid (11-beta)  
1272 dehydrogenase 1 gene, neuroticism and postpartum depression. *Journal of Affective Disorders*  
1273 **207**, 141-147 (2017).
- 1274 105. Zaconeta, A.M. et al. Cerebrospinal Fluid CRH Levels in Late Pregnancy Are Not Associated With  
1275 New-Onset Postpartum Depressive Symptoms. *J Clin Endocrinol Metab* **100**, 3159-64 (2015).
- 1276 106. Hahn-Holbrook, J., Fox, M. & Glynn, L.M. Letter to the Editor: Demonstration of Elevated  
1277 Cerebrospinal Fluid CRH Levels During Pregnancy Provides Support for (Not Against) the Link  
1278 Between CRH and Postpartum Depression. *J Clin Endocrinol Metab* **101**, L5-6 (2016).



- 1279 107. Pedersen, C. et al. Late pregnancy thyroid-binding globulin predicts perinatal depression.  
1280 *Psychoneuroendocrinology* **65**, 84-93 (2016).
- 1281 108. Bergink, V. et al. Comorbidity of autoimmune thyroid disorders and psychiatric disorders  
1282 during the postpartum period: a Danish nationwide register-based cohort study. *Psychol Med*,  
1283 1-9 (2017).
- 1284 109. Wesseloo, R., Kamperman, A.M., Bergink, V. & Pop, V.J.M. Thyroid peroxidase antibodies during  
1285 early gestation and the subsequent risk of first-onset postpartum depression: A prospective  
1286 cohort study. *J Affect Disord* **225**, 399-403 (2018).
- 1287 110. Groer, M.W. & Vaughan, J.H. Positive thyroid peroxidase antibody titer is associated with  
1288 dysphoric moods during pregnancy and postpartum. *J Obstet Gynecol Neonatal Nurs* **42**, E26-32  
1289 (2013).
- 1290 111. Anderson, G. & Maes, M. Postpartum depression: Psychoneuroimmunological underpinnings  
1291 and treatment. *Neuropsychiatric Disease and Treatment* **9**, 277-287 (2013).
- 1292 112. Osborne, L.M. & Monk, C. Perinatal depression--the fourth inflammatory morbidity of  
1293 pregnancy?: Theory and literature review. *Psychoneuroendocrinology* **38**, 1929-52 (2013).
- 1294 113. Haim, A. et al. A survey of neuroimmune changes in pregnant and postpartum female rats.  
1295 *Brain Behav Immun* **59**, 67-78 (2017).
- 1296 114. Nilsen-Hamilton, M. et al. Tissue involution and the acute phase response. *Ann N Y Acad Sci*  
1297 **995**, 94-108 (2003).
- 1298 115. Skalkidou, A. et al. Risk of postpartum depression in association with serum leptin and  
1299 interleukin-6 levels at delivery: a nested case-control study within the UPPSAT cohort.  
1300 *Psychoneuroendocrinology* **34**, 1329-37 (2009).
- 1301 116. Maes, M. et al. Immune activation in the early puerperium is related to postpartum anxiety and  
1302 depressive symptoms. *Psychoneuroendocrinology* **25**, 121-37 (2000).
- 1303 117. Maes, M. et al. Effects of pregnancy and delivery on serum concentrations of Clara Cell Protein  
1304 (CC16), an endogenous anticytokine: lower serum CC16 is related to postpartum depression.  
1305 *Psychiatry Res* **87**, 117-27 (1999).
- 1306 118. De Vriese, S.R., Christophe, A.B. & Maes, M. Lowered serum n-3 polyunsaturated fatty acid  
1307 (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered  
1308 n-PUFAs are related to major depression. *Life Sci* **73**, 3181-7 (2003).
- 1309 119. Corwin, E.J. et al. Bidirectional psychoneuroimmune interactions in the early postpartum  
1310 period influence risk of postpartum depression. *Brain Behav Immun* **49**, 86-93 (2015).
- 1311 120. Bergink, V. et al. Pre-eclampsia and first-onset postpartum psychiatric episodes: a Danish  
1312 population-based cohort study. *Psychol Med* **45**, 3481-9 (2015).
- 1313 121. Bergink, V. et al. Autoimmune Encephalitis in Postpartum Psychosis. *Am J Psychiatry* **172**, 901-  
1314 8 (2015).
- 1315 122. Bergink, V. et al. Immune system dysregulation in first-onset postpartum psychosis. *Biol*  
1316 *Psychiatry* **73**, 1000-7 (2013).
- 1317 123. Uchino, B.N., Cacioppo, J.T. & Kiecolt-Glaser, J.K. The relationship between social support and  
1318 physiological processes: a review with emphasis on underlying mechanisms and implications  
1319 for health. *Psychol Bull* **119**, 488-531 (1996).
- 1320 124. Dickerson, S.S., Zoccola, P.M. & Hooker, E. in *The Oxford handbook of positive psychology*  
1321 (2009).
- 1322 125. Association, A.P. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)* (American  
1323 Psychiatric Publishing, Arlington, VA, 2013).
- 1324 126. WHO, W.H.O. (World Health Organization, Geneva, 1992).
- 1325 127. Falah-Hassani, K., Shiri, R. & Dennis, C.L. The prevalence of antenatal and postnatal co-morbid  
1326 anxiety and depression: a meta-analysis. *Psychological Medicine* **47**, 2041-2053 (2017).
- 1327 128. Howard, L.M., Megnin-Viggars, O., Symington, I., Pilling, S. & Guideline Development, G.  
1328 Antenatal and postnatal mental health: summary of updated NICE guidance. *BMJ* **349**, g7394  
1329 (2014).

129. Di Florio, A. et al. The impact of education, country, race and ethnicity on the self-report of postpartum depression using the Edinburgh Postnatal Depression Scale. *Psychol Med*, 1-13 (2016).
130. Heron, J., McGuinness, M., Blackmore, E.R., Craddock, N. & Jones, I. Early postpartum symptoms in puerperal psychosis. *BJOG* **115**, 348-53 (2008).
131. Bergink, V., Lambregtse-van den Berg, M.P., Koorengevel, K.M., Kupka, R. & Kushner, S.A. First-onset psychosis occurring in the postpartum period: a prospective cohort study. *J Clin Psychiatry* **72**, 1531-7 (2011).
132. Kamperman, A.M., Veldman-Hoek, M.J., Wesseloo, R., Robertson Blackmore, E. & Bergink, V. Phenotypical characteristics of postpartum psychosis: A clinical cohort study. *Bipolar Disord* (2017).
133. Feeney, E.J., Groman, S.M., Taylor, J.R. & Corlett, P.R. Explaining Delusions: Reducing Uncertainty Through Basic and Computational Neuroscience. *Schizophr Bull* **43**, 263-272 (2017).
134. Muzik, M. et al. Ptsd Symptoms across Pregnancy and Early Postpartum among Women with Lifetime Ptsd Diagnosis. *Depress Anxiety* **33**, 584-91 (2016).
135. Kendall-Tackett, K.A. Violence against women and the perinatal period: the impact of lifetime violence and abuse on pregnancy, postpartum, and breastfeeding. *Trauma Violence Abuse* **8**, 344-53 (2007).
136. Schofield, C.A., Battle, C.L., Howard, M. & Ortiz-Hernandez, S. Symptoms of the anxiety disorders in a perinatal psychiatric sample: a chart review. *J Nerv Ment Dis* **202**, 154-60 (2014).
137. McGarry, J., Kim, H., Sheng, X., Egger, M. & Baksh, L. Postpartum depression and help-seeking behaviour. *Journal of Midwifery and Women's Health* **54**, 50-56 (2009).
138. Dennis, C.L. & Hodnett, E. Psychosocial and psychological interventions for treating postpartum depression. *Cochrane Database of Systematic Reviews* **Issue 4** (2007).
139. Guidelines, B.B.C.P. (ed. Blue, B.) (2011).
140. Siu, A.L. et al. Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. *JAMA* **315**, 380-7 (2016).
141. NICE. Antenatal and postnatal mental health: Clinical management and service guidance. The British Psychological Society & The Royal College of Psychiatrists. (National Institute for Health and Care Excellence (NICE). <http://guidance.nice.org.uk/cg192.www.nice.org.uk/CG45>, 2014).
142. Milgrom, J. & Gemmill, A.W. (eds.) Identifying Perinatal Depression and Anxiety: Evidence-based Practice in Screening, Psychosocial Assessment and Management (Wiley-Blackwell, Chichester, 2015).
143. Alliance, M.M.H.
144. Screening for perinatal depression: a missed opportunity (Lancet. 2016 Feb 6;387(10018):505. doi: 10.1016/S0140-6736(16)00265-8).
145. Cox, J. & Holden, J. Perinatal Mental Health. A Guide to the Edinburgh Postnatal Depression Scale (EPDS) (Gaskell, London, 2003).
146. Myers, E. et al. (Agency for Healthcare Research and Quality, Rockville, MD, 2013).
147. Hewitt, C. et al. Methods to identify postnatal depression in primary care: an integrated evidence synthesis and value of information analysis. *Health Technology Assessment* **13**, 1-145, 147-230 (2009).
148. Howard, L.M., Flach, C., Mehay, A., Sharp, D. & Tylee, A. The prevalence of suicidal ideation identified by the Edinburgh Postnatal Depression Scale in postpartum women in primary care: findings from the RESPOND trial. *BMC pregnancy and childbirth* **11**, 57 (2011).
149. Brealey, S.D., Hewitt, C., Green, J.M., Morrell, J. & Gilbody, S. Screening for postnatal depression—Is it acceptable to women and healthcare professionals? A systematic review and meta-synthesis. *Journal of Reproductive and Infant Psychology* **28**, 328-344 (2010).

- 1379 150. Gemmill, A.W., Leigh, B., Ericksen, J. & Milgrom, J. A survey of the clinical acceptability of  
1380 screening for postnatal depression in depressed and non-depressed women. *BMC Public Health*  
1381 **6**, 211 (2006).
- 1382 151. Wisner, K. et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with  
1383 screen-positive depression findings. *JAMA Psychiatry* **70**, 490-498 (2013).
- 1384 152. Beck, C.T. & Gable, R.K. Postpartum Depression Screening Scale: development and  
1385 psychometric testing. *Nursing research* **49**, 272-82 (2000).
- 1386 153. Beck, A.T., Steer, R.A. & Brown, G.K. Manual for the BDI-II (The Psychological Corporation, San  
1387 Antonio, TX, 1996).
- 1388 154. Kroenke, K., Spitzer, R.L. & Williams, J.B. The PHQ-9: validity of a brief depression severity  
1389 measure. *Journal of General Internal Medicine* **16**, 606-13 (2001).
- 1390 155. Yawn, B.P. et al. TRIPPD: A practice-based network effectiveness study of postpartum  
1391 depression screening and management. *The Annals of Family Medicine* **10**, 320-329 (2012).
- 1392 156. Whooley, M., Avins, A. & Miranda, J. Case-finding instruments for depression: two questions are  
1393 as good as many. *J Gen Intern Med* **12**, 439-445 (1997).
- 1394 157. Arroll, B., Smith, F.G., Kerse, N., Fishman, T. & Gunn, J. Effect of the addition of a "help" question  
1395 to two screening questions on specificity for diagnosis of depression in general practice:  
1396 diagnostic validity study. *BMJ* **331**, 884 (2005).
- 1397 158. Falah-Hassani, K., Shiri, R. & Dennis, C.L. The prevalence of antenatal and postnatal co-morbid  
1398 anxiety and depression: a meta-analysis. *Psychol Med* **47**, 2041-2053 (2017).
- 1399 159. Milgrom, J. et al. Feasibility study and pilot randomised trial of an antenatal depression  
1400 treatment with infant follow-up. *Archives of Women's Mental Health* **18**, 717-30 (2015).
- 1401 160. Matthey, S., Fisher, J. & Rowe, H. Using the Edinburgh postnatal depression scale to screen for  
1402 anxiety disorders: Conceptual and methodological considerations. *Journal of Affective Disorders*  
1403 **146**, 224-230 (2013).
- 1404 161. Somerville, S. et al. Detecting the severity of perinatal anxiety with the Perinatal Anxiety  
1405 Screening Scale (PASS). *Journal of Affective Disorders* **186**, 18-25 (2015).
- 1406 162. Spitzer, R.L., Kroenke, K., Williams, J.B. & Lowe, B. A brief measure for assessing generalized  
1407 anxiety disorder: the GAD-7. *Arch Intern Med* **166**, 1092-7 (2006).
- 1408 163. Lord, C., Rieder, A., Hall, G.B., Soares, C.N. & Steiner, M. Piloting the perinatal obsessive-  
1409 compulsive scale (POCS): development and validation. *J Anxiety Disord* **25**, 1079-84 (2011).
- 1410 164. Meltzer-Brody, S., Churchill, E. & Davidson, J.R. Derivation of the SPAN, a brief diagnostic  
1411 screening test for post-traumatic stress disorder. *Psychiatry Res* **88**, 63-70 (1999).
- 1412 165. Frey, B.N., Simpson, W., Wright, L. & Steiner, M. Sensitivity and specificity of the Mood Disorder  
1413 Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum  
1414 period. *Journal of Clinical Psychiatry* **73**, 1456-1461 (2012).
- 1415 166. Clark, C.T. et al. Does Screening with the MDQ and EPDS Improve Identification of Bipolar  
1416 Disorder in an Obstetrical Sample? *Depression and Anxiety* **32**, 518-26 (2015).
- 1417 167. Chessick, C.A. & Dimidjian, S. Screening for bipolar disorder during pregnancy and the  
1418 postpartum period. *Arch Women Ment Health* **13**, 233-248 (2010).
- 1419 168. Kelly, E. & Sharma, V. Diagnosis and treatment of postpartum bipolar depression. *Expert review*  
1420 *of neurotherapeutics* **10**, 1045-1051 (2010).
- 1421 169. Stanton, K. & Watson, D. Explicating the structure and relations of the Mood Disorder  
1422 Questionnaire: Implications for screening for bipolar and related disorders. *J Affect Disord* **220**,  
1423 72-78 (2017).
- 1424 170. Yawn, B.P., LaRusso, E.M., Bertram, S.L. & Bobo, W.V. in Identifying Perinatal Depression and  
1425 Anxiety 32-50 (John Wiley & Sons, Ltd, 2015).
- 1426 171. Milgrom, J. & Gemmill, A.W. in Applied Topics in Health Psychology (eds. Caltabiano, M. &  
1427 Ricciardelli, L.) 212-227 (Wiley, Chichester, 2013).
- 1428 172. O'Connor, E., Rossom, R.C., Henninger, M., Groom, H.C. & Burda, B.U. Primary care screening for  
1429 and treatment of depression in pregnant and postpartum women evidence report and

1430 systematic review for the US preventive services task force. *JAMA - Journal of the American*  
1431 *Medical Association* **315**, 388-406 (2016).

1432 173. Milgrom, J. et al. Internet Cognitive Behavioral Therapy for Women With Postnatal Depression:  
1433 A Randomized Controlled Trial of MumMoodBooster. *J Med Internet Res* **18**, e54 (2016).

1434 174. Wilkinson, A., Anderson, S. & Wheeler, S.B. Screening for and Treating Postpartum Depression  
1435 and Psychosis: A Cost-Effectiveness Analysis. *Maternal and Child Health Journal* **21**, 903-914  
1436 (2017).

1437 175. Werner, E., Miller, M., Osborne, L.M., Kuzava, S. & Monk, C. Preventing postpartum depression:  
1438 review and recommendations. *Archives of Women's Mental Health* **18**, 41-60 (2015).

1439 176. Dennis, C.L. & Dowswell, T. Psychosocial and psychological interventions for preventing  
1440 postpartum depression. *Cochrane Database Syst Rev*, CD001134 (2013).

1441 177. Morrell, C.J. et al. A systematic review, evidence synthesis and meta-analysis of quantitative  
1442 and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and  
1443 acceptability of interventions to prevent postnatal depression. *Health Technology Assessment*  
1444 **20**, 1-414 (2016).

1445 178. Payne, J.L. Recent Advances and Controversies in Peripartum Depression. *Curr Obstet Gynecol*  
1446 *Rep* **5**, 250-256 (2016).

1447 179. Wisner, K.L. & Wheeler, S.B. Prevention of recurrent postpartum major depression. *Hosp*  
1448 *Community Psychiatry* **45**, 1191-6 (1994).

1449 180. Dennis, C.L. & Dowswell, T. Interventions (other than pharmacological, psychosocial or  
1450 psychological) for treating antenatal depression. *Cochrane Database Syst Rev*, CD006795  
1451 (2013).

1452 181. Kwan, B.M., Dimidjian, S. & Rizvi, S.L. Treatment preference, engagement, and clinical  
1453 improvement in pharmacotherapy versus psychotherapy for depression. *Behav Res Ther* **48**,  
1454 799-804 (2010).

1455 182. Dennis, C.L. & Chung-Lee, L. Postpartum depression help-seeking barriers and maternal  
1456 treatment preferences: a qualitative systematic review. *Birth* **33**, 323-31 (2006).

1457 183. Cameron, E.E., Hunter, D., Sedov, I.D. & Tomfohr-Madsen, L.M. What do dads want? Treatment  
1458 preferences for paternal postpartum depression. *J Affect Disord* **215**, 62-70 (2017).

1459 184. de Camps Meschino, D., Philipp, D., Israel, A. & Vigod, S. Maternal-infant mental health:  
1460 postpartum group intervention. *Arch Womens Ment Health* **19**, 243-51 (2016).

1461 185. Dennis, C.L. & Hodnett, E. Psychosocial and psychological interventions for treating postpartum  
1462 depression. *Cochrane Database Syst Rev*, CD006116 (2007).

1463 186. Ashford, M.T., Olander, E.K. & Ayers, S. Computer- or web-based interventions for perinatal  
1464 mental health: A systematic review. *J Affect Disord* **197**, 134-46 (2016).

1465 187. Goodman, J.H., Watson, G.R. & Stubbs, B. Anxiety disorders in postpartum women: A systematic  
1466 review and meta-analysis. *J Affect Disord* **203**, 292-331 (2016).

1467 188. Challacombe, F.L. et al. A pilot randomized controlled trial of time-intensive cognitive-  
1468 behaviour therapy for postpartum obsessive-compulsive disorder: effects on maternal  
1469 symptoms, mother-infant interactions and attachment. *Psychol Med* **47**, 1478-1488 (2017).

1470 189. Bisson, J.I., Roberts, N.P., Andrew, M., Cooper, R. & Lewis, C. Psychological therapies for chronic  
1471 post-traumatic stress disorder (PTSD) in adults. *Cochrane Database Syst Rev*, CD003388  
1472 (2013).

1473 190. Molyneaux, E., Howard, L.M., McGeown, H.R., Karia, A.M. & Trevillion, K. Antidepressant  
1474 treatment for postnatal depression. *Cochrane Database Syst Rev*, CD002018 (2014).

1475 191. Milgrom, J. et al. Treatment of postnatal depression with cognitive behavioural therapy,  
1476 sertraline and combination therapy: a randomised controlled trial. *Aust N Z J Psychiatry* **49**,  
1477 236-45 (2015).

1478 192. Lam, R.W. et al. Effects of combined pharmacotherapy and psychotherapy for improving work  
1479 functioning in major depressive disorder. *Br J Psychiatry* **203**, 358-65 (2013).

- 1480 193. Lam, R.W. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical  
1481 Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease  
1482 Burden and Principles of Care. *Can J Psychiatry* **61**, 510-23 (2016).
- 1483 194. Khalifeh, H., Hunt, I.M., Appleby, L. & Howard, L.M. Suicide in perinatal and non-perinatal  
1484 women in contact with psychiatric services: 15 year findings from a UK national inquiry.  
1485 *Lancet Psychiatry* **3**, 233-42 (2016).
- 1486 195. Orsolini, L. & Bellantuono, C. Serotonin reuptake inhibitors and breastfeeding: a systematic  
1487 review. *Hum Psychopharmacol* **30**, 4-20 (2015).
- 1488 196. Sriraman, N.K., Melvin, K. & Meltzer-Brody, S. ABM Clinical Protocol #18: Use of  
1489 Antidepressants in Breastfeeding Mothers. *Breastfeed Med* **10**, 290-9 (2015).
- 1490 197. Dennis, C.L., Ross, L.E. & Herxheimer, A. Oestrogens and progestins for preventing and treating  
1491 postpartum depression. *Cochrane Database Syst Rev*, CD001690 (2008).
- 1492 198. Deligiannidis, K.M. & Freeman, M.P. Complementary and alternative medicine therapies for  
1493 perinatal depression. *Best Pract Res Clin Obstet Gynaecol* **28**, 85-95 (2014).
- 1494 199. Pritchett, R.V., Daley, A.J. & Jolly, K. Does aerobic exercise reduce postpartum depressive  
1495 symptoms? a systematic review and meta-analysis. *Br J Gen Pract* **67**, e684-e691 (2017).
- 1496 200. Meltzer-Brody, S. et al. Evaluating the clinical effectiveness of a specialized perinatal psychiatry  
1497 inpatient unit. *Arch Womens Ment Health* (2013).
- 1498 201. Glangeaud-Freudenthal, N.M., Howard, L.M. & Sutter-Dallay, A.L. Treatment - mother-infant  
1499 inpatient units. *Best Pract Res Clin Obstet Gynaecol* **28**, 147-57 (2014).
- 1500 202. Health, A.G.D.o. (Commonwealth of Australia, 2013).
- 1501 203. Bergink, V. et al. Treatment of psychosis and mania in the postpartum period. *Am J Psychiatry*  
1502 **172**, 115-23 (2015).
- 1503 204. Babu, G.N., Thippeswamy, H. & Chandra, P.S. Use of electroconvulsive therapy (ECT) in  
1504 postpartum psychosis-a naturalistic prospective study. *Arch Womens Ment Health* **16**, 247-51  
1505 (2013).
- 1506 205. Lichtenberg, P., Navon, R., Wertman, E., Dasberg, H. & Lerer, B. Post-partum psychosis in adult  
1507 GM2 gangliosidosis. A case report. *Br J Psychiatry* **153**, 387-9 (1988).
- 1508 206. Doucet, S., Jones, I., Letourneau, N., Dennis, C.L. & Blackmore, E.R. Interventions for the  
1509 prevention and treatment of postpartum psychosis: a systematic review. *Arch Womens Ment*  
1510 *Health* (2010).
- 1511 207. Gobbi, G. Quetiapine in postpartum psychosis. *J Clin Psychopharmacol* **34**, 744-5 (2014).
- 1512 208. Smith, B. & Dubovsky, S.L. Pharmacotherapy of mood disorders and psychosis in pre- and post-  
1513 natal women. *Expert Opin Pharmacother* **18**, 1703-1719 (2017).
- 1514 209. Meador, K.J. et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years  
1515 (NEAD study): a prospective observational study. *Lancet Neurol* **12**, 244-52 (2013).
- 1516 210. Bromley, R.L., Weston, J. & Marson, A.G. Maternal Use of Antiepileptic Agents During Pregnancy  
1517 and Major Congenital Malformations in Children. *JAMA* **318**, 1700-1701 (2017).
- 1518 211. Ornoy, A., Weinstein-Fudim, L. & Ergaz, Z. Antidepressants, Antipsychotics, and Mood  
1519 Stabilizers in Pregnancy: What Do We Know and How Should We Treat Pregnant Women with  
1520 Depression. *Birth Defects Res* **109**, 933-956 (2017).
- 1521 212. Bogen, D.L., Sit, D., Genovese, A. & Wisner, K.L. Three cases of lithium exposure and exclusive  
1522 breastfeeding. *Arch Womens Ment Health* **15**, 69-72 (2012).
- 1523 213. Viguera, A.C. et al. Lithium in breast milk and nursing infants: clinical implications. *Am J*  
1524 *Psychiatry* **164**, 342-5 (2007).
- 1525 214. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders  
1526 (American Psychiatric Press, Arlington, VA, 2013).
- 1527 215. Kahneman, D. & Deaton, A. High income improves evaluation of life but not emotional well-  
1528 being. *Proceedings of the National Academy of Sciences of the United States of America* **107**,  
1529 16489-93 (2010).

- 1530 216. Diego, M.A. & al., e. Withdrawn and intrusive maternal interaction style and infant frontal EEG  
1531 asymmetry shifts in infants. *Infant Behavior & Development* **29**, 220-229 (2006).
- 1532 217. Reck, C. et al. Interactive regulation of affect in postpartum depressed mothers and their  
1533 infants: an overview. *Psychopathology* **37**, 272-80 (2004).
- 1534 218. Murray, L. et al. Controlled trial of the short- and long-term effect of psychological treatment of  
1535 post-partum depression: 2. Impact on the mother-child relationship and child outcome. *British*  
1536 *Journal of Psychiatry* **182**, 420-7 (2003).
- 1537 219. Field, T.M. Early interactions between infants and their postpartum depressed mothers. *Infant*  
1538 *Behavior & Development* (2002).
- 1539 220. Lyons-Ruth, K. Contributions of the Mother-Infant Relationship to Dissociative, Borderline, and  
1540 Conduct Symptoms in Young Adulthood. *Infant Ment Health J* **29**, 203-218 (2008).
- 1541 221. Pearson, R.M. et al. Maternal depression during pregnancy and the postnatal period: risks and  
1542 possible mechanisms for offspring depression at age 18 years. *JAMA Psychiatry* **70**, 1312-9  
1543 (2013).
- 1544 222. Cooper, P.J., De Pascalis, L., Woolgar, M., Romaniuk, H. & Murray, L. Attempting to prevent  
1545 postnatal depression by targeting the mother-infant relationship: a randomised controlled  
1546 trial. *Prim Health Care Res Dev* **16**, 383-97 (2015).
- 1547 223. Abel, K.M., Webb, R.T., Salmon, M.P., Wan, M.W. & Appleby, L. Prevalence and predictors of  
1548 parenting outcomes in a cohort of mothers with schizophrenia admitted for joint mother and  
1549 baby psychiatric care in England. *J Clin Psychiatry* **66**, 781-9; quiz 808-9 (2005).
- 1550 224. Ware, J.E., Jr. & Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36). I.  
1551 Conceptual framework and item selection. *Medical Care* **30**, 473-83 (1992).
- 1552 225. Kalyoncu, U., Dougados, M., Daures, J.P. & Gossec, L. Reporting of patient-reported outcomes in  
1553 recent trials in rheumatoid arthritis: a systematic literature review. *Annals of the Rheumatic*  
1554 *Diseases* **68**, 183-90 (2009).
- 1555 226. Ware, J., Jr., Kosinski, M. & Keller, S.D. A 12-Item Short-Form Health Survey: construction of  
1556 scales and preliminary tests of reliability and validity. *Medical Care* **34**, 220-33 (1996).
- 1557 227. Zubaran, C. & Foresti, K. Investigating quality of life and depressive symptoms in the  
1558 postpartum period. *Women and birth : journal of the Australian College of Midwives* **24**, 10-6  
1559 (2011).
- 1560 228. Mogos, M.F., August, E.M., Salinas-Miranda, A.A., Sultan, D.H. & Salihu, H.M. A Systematic Review  
1561 of Quality of Life Measures in Pregnant and Postpartum Mothers. *Appl Res Qual Life* **8**, 219-250  
1562 (2013).
- 1563 229. Symon, A., MacDonald, A. & Ruta, D. Postnatal quality of life assessment: Introducing the  
1564 Mother-Generated Index. *Birth: Issues in Perinatal Care* **29**, 40-46 (2002).
- 1565 230. Hill, P.D., Aldag, J.C., Hekel, B., Riner, G. & Bloomfield, P. Maternal Postpartum Quality of Life  
1566 Questionnaire. *Journal of Nursing Measurement* **14**, 205-20 (2006).
- 1567 231. Huang, K., Tao, F., Liu, L. & Wu, X. Does delivery mode affect women's postpartum quality of life  
1568 in rural China? *Journal of Clinical Nursing* **21**, 1534-43 (2012).
- 1569 232. Ruta, D.A., Garratt, A.M., Leng, M., Russell, I.T. & MacDonald, L.M. A new approach to the  
1570 measurement of quality of life. The Patient-Generated Index. *Medical Care* **32**, 1109-26 (1994).
- 1571 233. Brenes, G.A. Anxiety, depression, and quality of life in primary care patients. *Prim Care*  
1572 *Companion J Clin Psychiatry* **9**, 437-43 (2007).
- 1573 234. Roberts, J., Lenton, P., Keetharuth, A.D. & Brazier, J. Quality of life impact of mental health  
1574 conditions in England: results from the adult psychiatric morbidity surveys. *Health Qual Life*  
1575 *Outcomes* **12**, 1477-7525 (2014).
- 1576 235. Barkin, J.L., Wisner, K.L., Bromberger, J.T., Beach, S.R. & Wisniewski, S.R. Assessment of  
1577 functioning in new mothers. *Journal of Womens Health* **19**, 1493-9 (2010).
- 1578 236. Sadat, Z., Abedzadeh-Kalahroudi, M., Kafaei Atrian, M., Karimian, Z. & Sooki, Z. The Impact of  
1579 Postpartum Depression on Quality of Life in Women After Child's Birth. *Iran Red Crescent Med J*  
1580 **16**, 5 (2014).

- 1581 237. Webster, J., Nicholas, C., Velacott, C., Cridland, N. & Fawcett, L. Quality of life and depression  
1582 following childbirth: impact of social support. *Midwifery* **27**, 745-9 (2011).
- 1583 238. Bodhare, T.N., Sethi, P., Bele, S.D., Gayatri, D. & Vivekanand, A. Postnatal quality of life,  
1584 depressive symptoms, and social support among women in southern India. *Women and Health*  
1585 **55**, 353-65 (2015).
- 1586 239. Bauer, A., Parsonage, M., Knapp, M., Iemmi, V. & Adelaja, B. (London School of Economics and  
1587 the Centre for Mental Health, London, 2014).
- 1588 240. Vliegen, N., Casalin, S. & Luyten, P. The course of postpartum depression: a review of  
1589 longitudinal studies. *Harvard Review of Psychiatry* **22**, 1-22 (2014).
- 1590 241. Dolman, C., Jones, I.R. & Howard, L.M. Women with bipolar disorder and pregnancy: factors  
1591 influencing their decision-making. *BJPsych Open* **2**, 294-300 (2016).
- 1592 242. Dolman, C., Jones, I. & Howard, L.M. Pre-conception to parenting: a systematic review and  
1593 meta-synthesis of the qualitative literature on motherhood for women with severe mental  
1594 illness. *Arch Womens Ment Health* **16**, 173-96 (2013).
- 1595 243. Paulson, J.F. & Bazemore, S.D. Prenatal and postpartum depression in fathers and its  
1596 association with maternal depression: a meta-analysis. *JAMA* **303**, 1961-9 (2010).
- 1597 244. Davis, R.N., Davis, M.M., Freed, G.L. & Clark, S.J. Fathers' depression related to positive and  
1598 negative parenting behaviors with 1-year-old children. *Pediatrics* **127**, 612-8 (2011).
- 1599 245. Hoffman, C., Dunn, D.M. & Njoroge, W.F.M. Impact of Postpartum Mental Illness Upon Infant  
1600 Development. *Curr Psychiatry Rep* **19**, 100 (2017).
- 1601 246. Paulson, J.F., Bazemore, S.D., Goodman, J.H. & Leiferman, J.A. The course and interrelationship  
1602 of maternal and paternal perinatal depression. *Archives of Women's Mental Health* **19**, 655-663  
1603 (2016).
- 1604 247. Lund, C. et al. Poverty and mental disorders: breaking the cycle in low-income and middle-  
1605 income countries. *Lancet* **378**, 1502-14 (2011).
- 1606 248. Allen, J., Balfour, R., Bell, R. & Marmot, M. Social determinants of mental health. *Int Rev*  
1607 *Psychiatry* **26**, 392-407 (2014).
- 1608 249. Naila, K. Gender, poverty, and inequality: a brief history of feminist contributions in the field of  
1609 international development. *Gender and Development* **23** (2015).
- 1610 250. Burns, P.A., Zunt, J.R., Hernandez, B. Intimate Partner Violence, Poverty, and Maternal Health  
1611 Care-Seeking Among Young Women in Kenya: a Cross-Sectional Analysis Informing the New  
1612 Sustainable Development Goals. *Global and Social Welfare* (2018).
- 1613 251. WHO, H.W. (World Health Organization, Geneva, 2014).
- 1614 252. Chisholm, D. et al. Scaling-up treatment of depression and anxiety: a global return on  
1615 investment analysis. *Lancet Psychiatry* **3**, 415-24 (2016).
- 1616 253. Chisholm, D., Lund, C. & Saxena, S. Cost of scaling up mental healthcare in low- and middle-  
1617 income countries. *Br J Psychiatry* **191**, 528-35 (2007).
- 1618 254. Rahman, A., Surkan, P.J., Cayetano, C.E., Rwagatare, P. & Dickson, K.E. Grand challenges:  
1619 integrating maternal mental health into maternal and child health programmes. *PLoS Med* **10**,  
1620 e1001442 (2013).
- 1621 255. Patel, V. et al. Addressing the burden of mental, neurological, and substance use disorders: key  
1622 messages from Disease Control Priorities, 3rd edition. *Lancet* **387**, 1672-85 (2016).
- 1623 256. Organization, B.o.W.H. (ed. [PDF], d.h.d.o.B.) (2013).
- 1624 257. Rahman, A., Malik, A., Sikander, S., Roberts, C. & Creed, F. Cognitive behaviour therapy-based  
1625 intervention by community health workers for mothers with depression and their infants in  
1626 rural Pakistan: a cluster-randomised controlled trial. *Lancet* **372**, 902-9 (2008).
- 1627 258. Rojas, G. et al. Treatment of postnatal depression in low-income mothers in primary-care  
1628 clinics in Santiago, Chile: a randomised controlled trial. *Lancet* **370**, 1629-37 (2007).
- 1629 259. Chibanda, D. et al. Group problem-solving therapy for postnatal depression among HIV-positive  
1630 and HIV-negative mothers in Zimbabwe. *J Int Assoc Provid AIDS Care* **13**, 335-41 (2014).

- 1631 260. Jahanfar, S., Howard, L.M. & Medley, N. Interventions for preventing or reducing domestic  
1632 violence against pregnant women. *Cochrane Database Syst Rev*, CD009414 (2014).  
1633 261. Shrestha, S.D., Pradhan, R., Tran, T.D., Gualano, R.C. & Fisher, J.R. Reliability and validity of the  
1634 Edinburgh Postnatal Depression Scale (EPDS) for detecting perinatal common mental  
1635 disorders (PCMDs) among women in low-and lower-middle-income countries: a systematic  
1636 review. *BMC Pregnancy Childbirth* **16**, 72 (2016).  
1637  
1638